Search

Your search keyword '"G. Selim"' showing total 37 results
Start Over Author "G. Selim" Language undetermined
37 results on '"G. Selim"'

1. The value of Real time PCR and High Resolution Ultrasound in Diagnosis of Suspected Pure Neural Leprosy

Author

Ahmed G. Selim, Fatma Eldesoky, Hamed A. Gobran, Nissreen E ELBadawy, and Mohammad A. Rashed

Subjects
medicine.medical_specialty, Real-time polymerase chain reaction, business.industry, Medicine, High resolution ultrasound, Radiology, business, Value (mathematics), Neural Leprosy
Abstract

Background: Cases with pure neural leprosy (PNL) are difficult in their diagnosis and usually loss the early management opportunity. Objective: to evaluate Real time PCR and high resolution ultrasonography of peripheral nerves as diagnostic tools in PNL. Methodology The study included 25 suspected PNL and 25 healthy controls. All patients were subjected to ultrasonography cross-sectional area (CSA) measurement. Fine needle aspiration (FNA) was obtained, and followed by Ziehl-Neelsen (ZN) staining, and real time PCR. Results: ZN staining demonstrated M leprae bacilli in only 8 cases while their DNA was detected in 92 % cases (Sensitivity of both were 100%, and 44.4%, respectively). Only the left median and right and left posterior tibial nerves CSA measurements showed good performance in distinguishing patients of PNL. Median nerve cut off=15.5 mm2 , with a sensitivity of 72%), and right and left posterior tibial nerves CSA Cut Off were 12, 11.5 mm2 with sensitivity of 76-84%. Conclusions: ultrasonography of suspected nerves and real time PCR of nerve aspirates are simple accurate tests for diagnosis of PNL.

Published
2021

2. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant

Author

Wei Jiang, Leighton E. Clancy, Selmir Avdic, Gaurav Sutrave, Janine Street, Renee Simms, Helen M. McGuire, Ellis Patrick, Adam S. Chan, Georgia McCaughan, Nadav Myers, Kenneth P. Micklethwaite, Vicki Antonenas, Adrian G. Selim, David Ritchie, Caroline M. Bateman, Peter J. Shaw, Emily Blyth, and David J. Gottlieb

Subjects
Epstein-Barr Virus Infections, Herpesvirus 4, Human, Cytomegalovirus Infections, Australia, Hematopoietic Stem Cell Transplantation, Cytomegalovirus, Humans, Transplantation, Homologous, Hematology, Antiviral Agents, Stem Cell Transplantation
Abstract

Virus-specific T-cells (VSTs) from third-party donors mediate short- and long-term antiviral effects in allogeneic hematopoietic stem cell transplant (HSCT) recipients with relapsed or refractory viral infections. We investigated early administration of third-party VSTs, together with antiviral therapy in patients requiring treatment for first cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection. Thirty HSCT patients were treated with 1 to 4 VST infusions (2 × 107 cells/m2; CMV n=27, EBV n=3) at a median of 4 days after initiation of antiviral treatment. The overall viral response rate was 100%, with a complete response (CR) rate of 94%. Of the 28 patients who achieved a CR, 23 remained virus PCR negative (n=9) or below quantitation limit (n=14) for the duration of follow-up. Four patients had brief episodes of quantifiable reactivation not requiring additional therapy, and one required a second infusion after initial CR, remaining PCR negative thereafter. All 3 patients treated for EBV post-transplant lymphoproliferative disorder achieved sustained CR. Rates of aGVHD and cGVHD after infusion were 13% and 23%, respectively. There were no serious infusion-related adverse events. VST infusion was associated with rapid recovery of CD8+CD45RA−CD62L− and a slower recovery of CD4+CD45RA−CD62L− effector memory T-cells; CMV-specific T-cells comprised up to 13% of CD8+ cells. At 1 year post-transplant, non-relapse mortality was 10%, cumulative incidence of relapse was 7%, overall survival was 88% and 25 of 27 patients had ECOG status of 0 or 1. Early administration of third-party VSTs in conjunction with antiviral treatment appears safe and leads to excellent viral control and clinical outcomes. Registered on Australian New Zealand Clinical Trials Registry as #ACTRN12618000343202.

Published
2022

3. An atypical case of Epstein-Barr virus-positive plasma cell post-transplant lymphoproliferative disorder successfully treated with adoptive cell therapy

Author

David Gottlieb, Emily Blyth, Leighton Clancy, David Ritchie, Elissa Atkins, Jessica Elliott, Ashish Bajel, Selmir Avdic, and Adrian G Selim

Subjects
medicine.medical_specialty, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Transplantation Conditioning, Plasma Cells, Paraproteinemias, T-Cell Antigen Receptor Specificity, Disease, Plasma cell, Immunotherapy, Adoptive, Post-transplant lymphoproliferative disorder, Cell therapy, Immunocompromised Host, Young Adult, Postoperative Complications, Internal medicine, medicine, Humans, Viremia, Hematology, business.industry, Remission Induction, Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Positive, Plasmapheresis, medicine.disease, Blood Viscosity, Combined Modality Therapy, Lymphoproliferative Disorders, Clone Cells, medicine.anatomical_structure, Immunoglobulin M, Immunology, Neoplastic Stem Cells, Female, Virus Activation, business, Immunosuppressive Agents, Paraproteins, T-Lymphocytes, Cytotoxic
Published
2021

4. CAR-T cell therapy: practical guide to routine laboratory monitoring

Author

Piers Blombery, Adrian Minson, Mary Ann Anderson, Simon J. Harrison, Adrian G Selim, and Michael Dickinson

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Malignancy, Immunotherapy, Adoptive, Pathology and Forensic Medicine, Cell therapy, 03 medical and health sciences, 0302 clinical medicine, Immune system, Refractory, Antigen, Internal medicine, Leukemia, B-Cell, Medicine, Humans, business.industry, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Chimeric antigen receptor, Lymphoma, Cytokine release syndrome, 030104 developmental biology, 030220 oncology & carcinogenesis, Lymphoma, Large B-Cell, Diffuse, business
Abstract

Chimeric antigen receptor (CAR)-T cell therapy is a genetically-modified cellular immunotherapy that has a current established role in the treatment of relapsed/refractory B-cell acute lymphoblastic leukaemia and diffuse large B-cell lymphoma, with emerging utility in a spectrum of other haematological and solid organ malignancies. It is associated with a number of characteristic toxicities, most notably cytokine release syndrome and neurotoxicity, for which laboratory testing can aid in the prediction of severity and in monitoring. Other toxicities, such as cytopenias/marrow hypoplasia, hypogammagloblinaemia and delayed immune reconstitution are recognised and require monitoring due to the implications for infection risk and prophylaxis. The detection or quantitation of circulating CAR-T can be clinically useful, and is achieved through both direct methods, if available, or indirect/surrogate methods. It is important that the laboratory is informed of the CAR-T therapy and target antigen whenever tissue is collected, both for response assessment and investigation of possible relapse, so that the expression of the relevant antigen can be assessed, in order to distinguish antigen-positive and -negative relapses. Finally, the measurement of circulating tumour DNA has an evolving role in the surveillance of malignancy, with evidence of its utility in the post-CAR-T setting, including predicting patients who will inevitably experience frank relapse, potentially allowing for pre-emptive therapy.

Published
2021

5. Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia

Author

Adrian G. Selim and Andrew S. Moore

Subjects
0301 basic medicine, Oncology, Acute promyelocytic leukemia, medicine.medical_specialty, Myeloid, Genetic heterogeneity, business.industry, Myeloid leukemia, medicine.disease, Minimal residual disease, Pathology and Forensic Medicine, body regions, Fusion gene, 03 medical and health sciences, Leukemia, 030104 developmental biology, 0302 clinical medicine, medicine.anatomical_structure, hemic and lymphatic diseases, 030220 oncology & carcinogenesis, Internal medicine, medicine, Molecular Medicine, business, Childhood Acute Lymphoblastic Leukemia
Abstract

The ability to sensitively monitor minimal residual disease (MRD) has played a key role in improving the management and outcomes for a number of leukemias, particularly acute promyelocytic leukemia and childhood acute lymphoblastic leukemia. By contrast, MRD monitoring in acute myeloid leukemia (AML) has been limited by variable assay methodologies and a relative paucity of patient-specific MRD markers. Inter- and intratumor genetic heterogeneity poses significant challenges for the identification of molecular markers suitable for MRD monitoring in AML, particularly for those cases without structural chromosomal rearrangements associated with fusion genes. Furthermore, the need to discriminate which mutations may be suitable for MRD monitoring creates additional complexity. The mainstay of current molecular MRD monitoring is real-time quantitative PCR, targeting fusion genes, mutations, and gene overexpression. New technologies, particularly next-generation sequencing approaches, offer new ways to overcome these limitations. Here, the authors review the techniques available for molecular MRD monitoring in AML and discuss their utility in clinical practice.

Published
2018

6. Hematopoietic stem cell transplantation for children with acute myeloid leukemia in second remission: A report from the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group

Author

Tracey A. O'Brien, Ian Nivison-Smith, Chris Fraser, Heather Tapp, Andrew S. Moore, Francoise Mechinaud, Frank Alvaro, Peter J. Shaw, Adrian G. Selim, Lochie Teague, and Catherine H. Cole

Subjects
Oncology, Male, Bone marrow transplant, medicine.medical_specialty, Neoplasm, Residual, Adolescent, medicine.medical_treatment, chemical and pharmacologic phenomena, Hematopoietic stem cell transplantation, Disease, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, Medicine, Humans, Registries, Child, Disease burden, Retrospective Studies, Chemotherapy, Hematology, business.industry, Remission Induction, Australia, Hematopoietic Stem Cell Transplantation, Infant, Newborn, Myeloid leukemia, Infant, Prognosis, Minimal residual disease, Survival Rate, Leukemia, Myeloid, Acute, surgical procedures, operative, 030220 oncology & carcinogenesis, Child, Preschool, Pediatrics, Perinatology and Child Health, Female, Neoplasm Recurrence, Local, business, 030215 immunology, Follow-Up Studies
Abstract

Approximately one-third of children with acute myeloid leukemia (AML) relapse, requiring re-treatment and allogeneic hematopoietic stem cell transplantation (HSCT). Although achieving second complete remission (CR2) prior to HSCT is desirable, once CR2 is attained, it is unclear if there is any benefit from further chemotherapy prior to HSCT. Moreover, although pre-HSCT minimal residual disease (MRD) has prognostic value in acute lymphoblastic leukemia, the benefit of MRD reduction after achieving CR prior to HSCT is less clear for AML. To address these questions, we analyzed data from pediatric transplant centers in Australia and New Zealand concerning relapsed childhood AML cases occurring between 1998 and 2013. Given the retrospective nature of our analysis and assay data available, we analyzed patients on the basis of measurable residual disease (MeRD) by any methodology, rather than MRD in the conventional sense. We observed improved overall survival (OS) in children receiving two chemotherapy cycles, compared to one cycle or three or more cycles pre-HSCT. Improved OS with two cycles remained significant for patients without MeRD after cycle 1. These data suggest that a second chemotherapy cycle pre-HSCT may improve survival by lowering disease burden. Prospective trials assessing strategies to reduce pre-HSCT MRD in relapsed childhood AML are warranted.

Published
2019

8. Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions

Author

Adrian G, Selim and Andrew S, Moore

Subjects
Leukemia, Myeloid, Acute, Neoplasm, Residual, Molecular Diagnostic Techniques, Gene Expression Regulation, Leukemic, Mutation, Humans
Abstract

The ability to sensitively monitor minimal residual disease (MRD) has played a key role in improving the management and outcomes for a number of leukemias, particularly acute promyelocytic leukemia and childhood acute lymphoblastic leukemia. By contrast, MRD monitoring in acute myeloid leukemia (AML) has been limited by variable assay methodologies and a relative paucity of patient-specific MRD markers. Inter- and intratumor genetic heterogeneity poses significant challenges for the identification of molecular markers suitable for MRD monitoring in AML, particularly for those cases without structural chromosomal rearrangements associated with fusion genes. Furthermore, the need to discriminate which mutations may be suitable for MRD monitoring creates additional complexity. The mainstay of current molecular MRD monitoring is real-time quantitative PCR, targeting fusion genes, mutations, and gene overexpression. New technologies, particularly next-generation sequencing approaches, offer new ways to overcome these limitations. Here, the authors review the techniques available for molecular MRD monitoring in AML and discuss their utility in clinical practice.

Published
2017

9. DIALYSIS CARDIOVASCULAR COMPLICATIONS 1

Author

D. C. Wheeler, S. Abdalla, G. Chertow, P. Parfrey, C. Herzog, I. Mikolasevic, S. Racki, V. Lukenda, S. Milic, B. Devcic, L. Orlic, M. M. Suttorp, T. Hoekstra, G. Ocak, A. T. N. Van Diepen, I. Ott, M. Mittelman, T. J. Rabelink, R. T. Krediet, F. W. Dekker, S. Simone, M. P. S. Dell'Oglio, M. Ciccone, R. Corciulo, G. Castellano, C. Balestra, G. Grandaliano, L. Gesualdo, G. Pertosa, M. Nishida, M. Ando, K. Karasawa, Y. Iwamoto, K. Tsuchiya, K. Nitta, M. Krzanowski, K. Janda, M. Gajda, P. Dumnicka, D. Fedak, G. Lis, P. Ja kowski, J. A. Litwin, W. Su owicz, G. R. Freitas, V. B. Silva, H. Abensur, C. Luders, B. J. Pereira, M. C. Castro, R. B. Oliverira, R. M. Moyses, R. M. Elias, B. C. Silva, H. Tekce, S. Ozturk, G. Aktas, B. Kin Tekce, A. Erdem, M. Ozyasar, T. Taslamacioglu Duman, M. Yazici, A. Kirkpantur, M. M. Balci, A. Turkvatan, B. Afsar, M. Alkis, F. Mandiroglu, L. Voroneanu, D. Siriopol, I. Nistor, M. Apetrii, S. Hogas, M. Onofriescu, A. Covic, W. S. An, S. E. Kim, Y. K. Son, Y. J. Oh, S. Gelev, S. Toshev, L. Trajceska, G. Selim, P. Dzekova, A. Shikole, J. Park, J. S. Lee, E.-S. Shin, S. H. Ann, S.-J. Kim, H. C. Chung, W. Sulowicz, U. Elewa, W. Bichari, K. Abo-Seif, S. Seferi, M. Rroji, E. Likaj, N. Spahia, M. Barbullushi, N. Thereska, C. M. Kopecky, B. Genser, W. Maerz, C. Wanner, M. D. Saemann, T. Weichhart, S. Sezer, B. Gurlek Demirci, E. Tutal, Z. Bal, M. Erkmen Uyar, F. N. Ozdemir Acar, B. Macunluoglu, A. Atakan, E. Ari Bakir, P. Georgianos, P. A. Sarafidis, D. N. Stamatiadis, V. Liakopoulos, P. E. Zebekakis, A. Papagianni, A. N. Lasaridis, N. Eftimovska - Otovic, E. Babalj-Banskolieva, S. Kostadinska-Bogdanoska, R. Grozdanovski, M. Aono, Y. Sato, M. El Amrani, M. Asserraji, M. Benyahia, Y.-K. Lee, S. R. Choi, A. Cho, J.-K. Kim, M.-J. Choi, S. J. Kim, J.-W. Yoon, J.-R. Koo, H. J. Kim, J.-W. Noh, H. Inagaki, N. Yokota, S. Chiyotanda, K. Fukami, S. Fujimoto, Z. Kendi Celebi, S. Kutlay, S. Sengul, G. Nergizoglu, S. Erturk, K. Ates, K. A. Vishnevskii, A. S. Rumyantsev, A. Y. Zemchenkov, A. V. Smirnov, B. Reinhardt, R. Knaup, V. Esteve Simo, J. Carneiro Oliveira, F. Moreno Guzman, M. Fulquet Nicolas, M. Pou Potau, A. Saurina Sole, V. Duarte Gallego, M. Ramirez De Arellano Serna, K. Turkmen, L. Demirtas, E. M. Akbas, E. M. Bakirci, M. Buyuklu, A. Timuroglu, P. I. Georgianos, A. Karpetas, T. Taira, K. Nohtomi, T. Takemura, T. Chiba, T. Hirano, C.-T. Chang, C.-C. Huang, C.-J. Chen, A. Mohamed, H. Kanai, Y. Tamura, Y. Kaizu, A. Kali, O. Yayar, B. Erdogan, B. Eser, Z. Ercan, M. Buyukbakkal, O. Merhametsiz, A. Haspulat, T. Yildirim, B. Bozkurt, M. D. Ayli, D. Gokustun, A. Markaki, M. Grammatikopoulou, G. Fragkiadakis, K. Stylianou, M. Venyhaki, V. Chatzi, O. Stojceva-Taneva, L. Tozija, P. Dzekova-Vidimliski, Z. Petronievic, A. Sikole, V. Moyseyenko, T. Nykula, R. T. Fernandes, D. V. Barreto, G. G. C. Rodrigues, A. Misael, C. T. Branco-Martins, and F. C. Barreto

Subjects
Transplantation, medicine.medical_specialty, Nephrology, business.industry, medicine, Intensive care medicine, business, Dialysis (biochemistry)
Published
2014

10. DIALYSIS. PATHOPHYSIOLOGY AND CLINICAL STUDIES

Author

J. K. Humalda, S. Assa, G. J. Navis, C. F. M. Franssen, M. H. De Borst, H. Ogawa, Y. Ota, T. Watanabe, Y. Watanabe, H. Nishii, A. Sato, J. Waniewski, M. Debowska, A. Wojcik-Zaluska, A. Ksiazek, W. Zaluska, C. M. Guastoni, C. Turri, L. Toma, G. Rombola, G. Frattini, G. Romei Longhena, U. Teatini, D.-C. Siriopol, S. Stuard, A. Ciolan, G. Mircescu, D. Raluca, I. Nistor, A. Covic, C. L. De Roij Van Zuijdewijn, I. Chapdelaine, M. J. Nube, P. J. Blankestijn, M. L. Bots, S. J. Konings, M. A. Van Den Dorpel, N. C. Van Der Weerd, P. M. Ter Wee, M. P. Grooteman, P. S. Djuric, A. Jankovic, J. Tosic, S. Bajcetic, T. Damjanovic, J. Popovic, N. Dimkovic, J. Marinkovic, Z. Djuric, V. Knezevic, T. Lazarevic, S. Ljubenovic, R. Markovic, V. Rabrenovic, L. Djukanovic, V. Radovic Maslarevic, V. Mathrani, P. Drew, J. I. Chess, A. I. Williams, S. Robertson, M. Jibani, V. I. Aithal, M. Kumwenda, G. Roberts, A. I. Mikhail, A. E. Grzegorzewska, G. Ostromecki, A. Mostowska, A. Sowi ska, P. P. Jagodzi ski, H.-Y. Wu, H.-Y. Chen, S.-P. Hsu, M.-F. Pai, J.-Y. Yang, Y.-S. Peng, M. Hirose, T. Hasegawa, N. Kaneshima, F. Sasai, D. Komukai, K. Takahashi, F. Koiwa, K. Shishido, A. Yoshimura, G. Selim, O. Stojceva-Taneva, L. Tozija, P. Dzekova-Vidimliski, L. Trajceska, Z. Petronievic, S. Gelev, V. Amitov, A. Sikole, S. J. Moon, S. Y. Yoon, D. H. Shin, J. E. Lee, H.-J. Kim, H.-C. Park, D. Hadjiyannakos, V. Filiopoulos, G. Loukas, S. Pagonis, C. Andriopoulos, A. Drakou, D. Vlassopoulos, C. Catarino, P. Cunha, S. Ribeiro, P. Rocha-Pereira, F. Reis, M. Sameiro-Faria, V. Miranda, E. Bronze-Rocha, L. Belo, E. Costa, A. Santos-Silva, A. De Mauri, M. Brambilla, D. Chiarinotti, D. Lizio, R. Matheoud, N. Conti, M. M. Conte, A. Carriero, M. De Leo, A. V. Karpetas, P. A. Sarafidis, P. I. Georgianos, G. Koutroumpas, D. Divanis, P. Vakianis, G. Tzanis, K. Raptopoulou, A. Protogerou, D. Stamatiadis, C. Syrganis, V. Liakopoulos, G. Efstratiadis, A. N. Lasaridis, M. Tersi, D. N. Stamatiadis, P. Kuczera, M. Adamczak, A. Wiecek, S. Bove, B. Giacon, R. Corradini, E. Prati, M. Brognoli, A. Tommasi, L. Sereni, G. Palladino, H. Moriya, Y. Mochida, K. Ishioka, M. Oka, K. Maesato, S. Hidaka, T. Ohtake, S. Kobayashi, A. Moura, J. Madureira, P. Alija, J. C. Fernandes, J. G. Oliveira, M. Lopez, M. Filgueiras, L. Amado, M. Vieira, J.-H. Seok, H. Y. Choi, S. K. Ha, H. C. Park, M. Bossola, A. Laudisio, M. Antocicco, L. Tazza, G. Colloca, M. Tosato, G. Zuccala, E. M. Ettema, J. Kuipers, H. Groen, R. T. Gansevoort, K. Stade, S. J. L. Bakker, C. A. J. M. Gaillard, R. Westerhuis, J. Bacchetta, K. Couchoud, S. Semlali, A.-L. Sellier-Leclerc, A. Bertholet-Thomas, R. Cartier, P. Cochat, B. Ranchin, J. C. Kim, K. Park, C. Van Ende, D. Wilmes, F. E. Lecouvet, L. Labriola, R. Cuvelier, G. Van Ingelgem, M. Jadoul, C. Doriana, P. David, F. Capurro, M. Brustia, C. E. Ruva, S. Giungi, E. Di Stasio, S. Lemesch, B. Leber, A. Horvath, W. Ribitsch, G. Schilcher, G. Zettel, M. Tawdrous, A. R. Rosenkranz, V. Stadlbauer-Kollner, H. Matsushima, A. Oyama, E. Bosch Benitez-Parodi, E. Baamonde Laborda, F. Batista Garcia, G. Perez Suarez, G. Anton Perez, C. Garcia Canton, A. Toledo Gonzalez, M. M. Lago Alonso, M. D. Checa Andres, G. Cobo, C. Di Gioia, R. Camacho, C. Garcia Lacalle, O. Ortega, I. Rodriguez, J. Herrero, A. Oliet, M. Ortiz, C. Mon, A. Vigil, P. Gallar, V. Pellu, P. E. Nebiolo, K. Sasaki, S. Yamguchi, A. Hesaka, E. Iwahashi, S. Sakai, T. Fujimoto, S. Minami, Y. Fujita, K. Yokoyama, E. Shutov, G. Ryabinskya, S. Lashutin, E. Gorelova, E. Volodicheva, M. A. Podesta, G. Cancarini, D. Cucchiari, A. Montanelli, S. Badalamenti, G. Graziani, E. Distasio, I. Pchelin, A. Shishkin, Y. Fedorova, C.-C. Kao, T.-S. Chu, T.-J. Tsai, K.-D. Wu, M.-S. Wu, V. Raikou, P. Kaisidis, E. Tsamparlis, P. Kanellopoulos, J. Boletis, A. Ueda, A. Hirayama, S. Owada, K. Nagai, C. Saito, and K. Yamagata

Subjects
03 medical and health sciences, Transplantation, medicine.medical_specialty, 0302 clinical medicine, Nephrology, business.industry, 030232 urology & nephrology, medicine, 030204 cardiovascular system & hematology, Intensive care medicine, Dialysis (biochemistry), business, Pathophysiology
Published
2014

11. Antibiotics for ventilator-associated pneumonia

Author

Adrian G Selim, Leonardo Seoane, Lauren E. Arthur, Russell S Kizor, and Mieke L van Driel

Subjects
Adult, Medicine General & Introductory Medical Sciences, 0301 basic medicine, business.industry, 030106 microbiology, Pneumonia, Ventilator-Associated, Empirical Research, Anti-Bacterial Agents, 03 medical and health sciences, 0302 clinical medicine, Carbapenems, Cause of Death, Humans, Medicine, Drug Therapy, Combination, Pharmacology (medical), 030212 general & internal medicine, business, Randomized Controlled Trials as Topic
Abstract

BACKGROUND: Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic therapy based on the patients' risk of colonisation by an organism with multidrug resistance. The selection of initial antibiotic therapy in VAP is important, as inappropriate initial antimicrobial treatment is associated with higher mortality and longer hospital stay in intensive care unit (ICU) patients. While guidelines exist for the antibiotic treatment of hospital‐acquired pneumonia (HAP) from the American Thoracic Society and the British Society for Antimicrobial Chemotherapy, there are many limitations in the quality of available evidence. This systematic review aimed to summarise the results of all randomised controlled trials (RCTs) that compare empirical antibiotic regimens for VAP. OBJECTIVES: The primary objective of this review was to assess the effect of different empirical antimicrobial therapies on the survival and clinical cure of adult patients with ventilator‐associated pneumonia (VAP). Secondary objectives included reporting the incidence of adverse events, new superinfections, length of hospital stay, and length of intensive care unit (ICU) stay associated with these therapies. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS, CINAHL and Web of Science to December 2015; we searched ClinicalTrials.gov to September 2016. SELECTION CRITERIA: Two review authors independently assessed RCTs comparing empirical antibiotic treatments of VAP in adult patients, where VAP was defined as new‐onset pneumonia that developed more than 48 hours after endotracheal intubation. Physicians and researchers were not required to be blinded for inclusion in this review. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted study data. We pooled studies and analysed them in two ways. We examined monotherapy, or a single experimental antimicrobial drug, versus combination therapy, or multiple experimental antimicrobial drugs. We also examined carbapenem therapy versus non‐carbapenem therapy. MAIN RESULTS: We included 12 studies with 3571 participants. All included studies examined the empiric use of one antimicrobial regimen versus another for the treatment of adults with VAP, but the particular drug regimens examined by each study varied. There was potential for bias because some studies did not report outcomes for all participants. All but one study reported sources of funding or author affiliations with pharmaceutical companies. We found no statistical difference in all‐cause mortality between monotherapy and combination therapy (N = 4; odds ratio (OR) monotherapy versus combination 0.97, 95% confidence interval (CI) 0.73 to 1.30), clinical cure (N = 2; OR monotherapy versus combination 0.88, 95% CI 0.56 to 1.36), length of stay in ICU (mean difference (MD) 0.65, 95% CI 0.07 to 1.23) or adverse events (N = 2; OR monotherapy versus combination 0.93, 95% CI 0.68 to 1.26). We downgraded the quality of evidence for all‐cause mortality, adverse events, and length of ICU stay to moderate for this comparison. We determined clinical cure for this comparison to be of very low‐quality evidence. For our second comparison of combination therapy with optional adjunctives only one meta‐analysis could be performed due to a lack of trials comparing the same antibiotic regimens. Two studies compared tigecycline versus imipenem‐cilastatin for clinical cure in the clinically evaluable population and there was a statistically significant increase in clinical cure for imipenem‐cilastatin (N = 2; OR tigecycline versus imipenem‐cilastatin 0.44, 95% CI 0.23 to 0.84). Of importance, this effect was due to a single study. We found no statistical difference in all‐cause mortality between carbapenem and non‐carbapenem therapies (N = 1; OR carbapenem versus non‐carbapenem 0.59, 95% CI 0.30 to 1.19) or adverse events (N = 3; OR carbapenem versus non‐carbapenem 0.78, 95% CI 0.56 to 1.09), but we found that carbapenems are associated with a statistically significant increase in the clinical cure (N = 3; OR carbapenem versus non‐carbapenem 1.53, 95% CI 1.11 to 2.12 for intention‐to‐treat (ITT) analysis and N = 2; OR carbapenem versus non‐carbapenem 2.29, 95% CI 1.19 to 4.43 for clinically evaluable patients analysis). For this comparison we downgraded the quality of evidence for mortality, and clinical cure (ITT and clinically evaluable populations) to moderate. We determined the quality of evidence for adverse events to be low. AUTHORS' CONCLUSIONS: We did not find a difference between monotherapy and combination therapy for the treatment of people with VAP. Since studies did not identify patients with increased risk for multidrug‐resistant bacteria, these data may not be generalisable to all patient groups. However, this is the largest meta‐analysis comparing monotherapy to multiple antibiotic therapies for VAP and contributes further evidence to the safety of using effective monotherapy for the empiric treatment of VAP. Due to lack of studies, we could not evaluate the best antibiotic choice for VAP, but carbapenems as a class may result in better clinical cure than other tested antibiotics.

Published
2016

13. Vascular access

Author

L. Coentrao, C. Ribeiro, C. Santos-Araujo, R. Neto, M. Pestana, E. Rahman, H. Rahman, D. Ahmed, D. Mousa, M. El Bishlawi, H. Shibahara, N. Shibahara, S. Takahashi, E. Dupuis, X. Duval, Q. Dornic, C. Bonnal, J.-C. Lucet, O. Cerceau, C. Randoux, C. Balde, F. Besson, F. Mentre, F. Vrtovsnik, G. Koutroubas, P. Malindretos, G. Zagotsis, P. Makri, C. Syrganis, E. Mambelli, E. Mancini, C. Elia, V. Guadagno, M. G. Facchini, A. Zucchelli, M. Grazia, L. Patregnani, A. Santoro, G. Stefan, S. Stancu, C. Capusa, O. R. Ailioaiei, G. Mircescu, S. Anwar, C. Little, R. Kingston, P. Diwakar, R. Kaikini, E. Nikolaou, G. Loukas, A. Sabry, K. Alsaran, S. Al Sherbeiny, M. Abdulkader, I. Kwak, S. Song, E. Seong, S. Lee, D. Lee, I. Kim, H. Rhee, F. Silva, J. Queiros, J. Malheiro, A. Cabrita, A. Rocha, P. Bamidis, C. Liaskos, I. Chryssogonidis, C. Frantzidis, A. Papagiannis, D. Vrochides, A. Lasaridis, P. Nikolaidis, S. Kotwal, C. Muir, C. Hawley, P. Snelling, M. Gallagher, M. Jardine, K. Shibata, Y. Toya, S. Umemura, T. Iwamoto, S. Ono, E. Ikeda, A. Kitazawa, T. Kuji, N. Koguchi, H. Satta, M. Nishihara, S. Kawata, T. Kaneda, Y. Yamada, T. Murakami, M. Yanagi, G. Yasuda, S. Mathieu, D. Yves, T. Jean-Michel, Q. Nicolas, C. Jean-Francois, M. Ibrahim, M. Abdel Salam, A. Awadalla, W. Bichari, S. Zaki, R. Roca-Tey, R. Samon, O. Ibrik, A. Roda, J. C. Gonzalez-Oliva, R. Martinez-Cercos, J. Viladoms, C.-C. Lin, W.-C. Yang, Y.-O. Kim, S.-A. Yoon, Y.-S. Yun, H.-C. Song, B.-S. Kim, M.-A. Cheong, T. Ogawa, T. Kiba, S. Okazaki, M. Hatano, M. Iwanaga, C. Noiri, A. Matsuda, H. Hasegawa, T. Mitarai, A. DI Napoli, D. DI Lallo, L. Tazza, C. De Cicco, M. F. Salvatori, S. Chicca, G. Guasticchi, S. Gelev, L. Trajceska, E. Srbinovska, S. Pavleska, A. Oncevski, P. Dejanov, V. Gerasomovska, G. Selim, A. Sikole, S. Wilson, T. Mayne, M. Krishnan, J. Holland, A. Volz, L. Good, A. Nissenson, A. Stavroulopoulos, V. Aresti, G. Maragkakis, S. Kyriakides, C. Rikker, E. Juhasz, L. Tornoci, S. Tovarosi, J. Greguschik, O. Mag, L. Rosivall, T. Golebiowski, E. Watorek, M. Kusztal, K. Letachowicz, W. Letachowicz, K. Madziarska, H. Augustyniak Bartosik, M. Krajewska, W. Weyde, M. Klinger, A. Capitanini, S. Lange, A. Cupisti, T. Schier, G. Gobel, C. Bosmuller, I. Gruber, M. Tiefenthaler, T. Shipley, J. Adam, D. Sweeney, S. Fenwick, H. Mansy, S. Ahmed, I. Moore, P. Vigeral, S. Saksi, M. Flamant, H. Boulanger, W.-D. Park, M. A. Cheong, M. Nikam, A. Tavakoli, E. Chemla, J. Evans, H. Malete, L. Matyas, I. Mogan, M. Lazarides, A. Ebner, Y. Shi, J. Zhang, J. Cheng, L. R. Frank, H. Melanie, B. Dominique, G. Michel, K. Ikeda, T. Yasuda, H. Yotueda, L. Ebah, A. Jayanti, D. Kanigicherla, A. Summers, G. Manley, G. Dutton, N. Chalmers, S. Mitra, I.-A. Checherita, A. Niculae, D. Radulescu, C. David, F. L. Turcu, A. Ciocalteu, V. Persic, J. Buturovic-Ponikvar, R. Ponikvar, M. Touam, V. Menoyo, T. Drueke, M. Rifaat, C. Muresan, M. Abtahi, Z. Koochakipour, D. Joly, J. Baharani, S. Rizvi, K. P. Ng, L. Buzzi, C. Sarcina, E. Alberghini, F. Ferrario, I. Baragetti, G. Santagostino, S. Furiani, E. Corghi, V. Terraneo, F. Rastelli, G. Bacchini, C. Pozzi, M. Adorati Menegato, R. Mortellaro, A. Locicero, A. Romano, P. P. Manzini, D. Steckiph, S. Shintaku, H. Kawanishi, M. Moriishi, M. Bansyodani, S. Nakamura, M. Saito, S. Tsuchiya, F. Barros, R. Vaz, B. Carvalho, P. Martins, E. Likaj, S. Seferi, M. Rroji, A. Idrizi, A. Duraku, M. Barbullushi, and N. Thereska

Subjects
Transplantation, Nephrology
Published
2013

14. Pathophysiology and clinical studies in CKD 5D

Author

J. G. Raimann, F. Gotch, M. Keen, P. Kotanko, N. W. Levin, A. Pierratos, R. Lindsay, G. Severova-Andreevska, L. Trajceska, S. Gelev, G. Selim, A. Sikole, S. Y. Yoon, S. D. Hwang, D. K. Cho, Y. H. Cho, S. J. Moon, W. Ribitsch, P. J. Schreiner, M. Uhlmann, G. Schilcher, V. Stadlbauer, J. H. Horina, A. R. Rosenkranz, D. Schneditz, I. Kiss, L. Kerkovits, C. Ambrus, I. Kulcsar, J. Szegedi, A. Benke, B. Borbas, S. Ferenczi, M. Hengsperger, S. Kazup, L. Nagy, J. Nemeth, A. Rozinka, T. Szabo, T. Szelestei, E. Toth, G. Varga, G. Wagner, G. Zakar, L. Gergely, A. Tisler, Z. Kiss, S. Sasaki, M. Miyamato, A. Nomura, K. Koitabashi, H. Nishiwaki, T. Suzuki, D. Uchida, H. Kawarazaki, Y. Shibagaki, K. Kimura, C. Libetta, C. Martinelli, E. Margiotta, I. Borettaz, M. Canevari, P. Esposito, V. Sepe, A. Dal Canton, P. Pateinakis, C. Dimitriadis, A. Papagianni, S. Douma, G. Efstratiadis, D. Memmos, C. L. Nelson, P. J. Dunstan, R. Zwiech, Y. Hasuike, K. Yanase, S. Hamahata, T. Nagai, M. Yahiro, S. Kaibe, A. Kida, Y. Nagasawa, T. Kuragano, T. Nakanishi, J. S. Kim, J. W. Yang, S. O. Choi, B. G. Han, J. H. Chang, A. J. Kim, H. S. Kim, H. Ro, J. Y. Jung, H. H. Lee, W. Chung, H. Tanaka, T. Kita, K. Okamoto, M. Mikami, R. Sakai, E. Lojacono, B. Votta, T. Rampino, M. Gregorini, A. Amore, R. Coppo, M. M. S. ElSharkawy, M. Kamel, M. Elhamamsy, S. Allam, J.-H. Ryu, S. Lee, S. C. Hong, S.-J. Kim, D.-H. Kang, D.-R. Ryu, K. B. Choi, T. Kiraz, A. Yalcin, M. Akay, G. Sahin, A. Musmul, Y. Kamijo, H. Horiuchi, H. Iida, K. Saito, R. Furutera, Y. Ishibashi, M. Sidiropoulou, S. Patsialas, M. Angelopoulos, M. Torreggiani, N. Serpieri, M. Arazzi, V. Esposito, M. Calatroni, E. La Porta, D. Catucci, G. Montagna, L. Semeraro, E. Efficace, V. Piazza, L. Picardi, G. Villa, C. Esposito, J. C. Kim, E. Hwang, K. Park, H. Karakizlis, K. Bohl, B. Kortus-Goetze, R. Dodel, J. Hoyer, A. Cinar, R. Kazancioglu, A. T. Isik, E. Aydemir, B. Gorcin, J. Radic, D. Ljutic, M. Radic, V. Kovacic, M. Sain, K. Dodig Curkovic, A. E. Grzegorzewska, L. Niepolski, J. Sikora, P. Jagodzinski, A. Sowinska, V. Sirolli, C. Rossi, A. Di Castelnuovo, P. Felaco, L. Amoroso, M. Zucchelli, D. Ciavardelli, P. Sacchetta, A. Urbani, A. Arduini, M. Bonomini, T. Inoue, K. Okano, Y. Tsuruta, K. Tsuchiya, T. Akiba, K. Nitta, and D. Pajzderski

Subjects
Transplantation, Nephrology
Published
2013

15. Epidemiology and outcome research in CKD 5D

Author

L. Coentrao, C. Ribeiro, C. Santos-Araujo, R. Neto, M. Pestana, W. Kleophas, A. Karaboyas, Y. LI, J. Bommer, R. Pisoni, B. Robinson, F. Port, G. Celik, B. Burcak Annagur, M. Yilmaz, T. Demir, F. Kara, K. Trigka, P. Dousdampanis, N. Vaitsis, S. Aggelakou-Vaitsi, K. Turkmen, I. Guney, F. Turgut, L. Altintepe, H. Z. Tonbul, E. Abdel-Rahman, P. Sclauzero, G. Galli, G. Barbati, M. Carraro, G. O. Panzetta, M. Van Diepen, M. Schroijen, O. Dekkers, F. Dekker, A. Sikole, G. Severova- Andreevska, L. Trajceska, S. Gelev, V. Amitov, S. Pavleska- Kuzmanovska, H. Rayner, R. Vanholder, M. Hecking, B. Jung, M. Leung, F. Huynh, T. Chung, S. Marchuk, M. Kiaii, L. Er, R. Werb, C. Chan-Yan, M. Beaulieu, P. Malindretos, P. Makri, G. Zagkotsis, G. Koutroumbas, G. Loukas, E. Nikolaou, M. Pavlou, E. Gourgoulianni, M. Paparizou, M. Markou, E. Syrgani, C. Syrganis, J. Raimann, L. A. Usvyat, V. Bhalani, N. W. Levin, P. Kotanko, X. Huang, P. Stenvinkel, A. R. Qureshi, U. Riserus, T. Cederholm, P. Barany, O. Heimburger, B. Lindholm, J. J. Carrero, J. H. Chang, J. Y. Sung, J. Y. Jung, H. H. Lee, W. Chung, S. Kim, J. S. Han, K. Y. Na, A. Fragoso, A. Pinho, A. Malho, A. P. Silva, E. Morgado, P. Leao Neves, N. Joki, Y. Tanaka, M. Iwasaki, S. Kubo, T. Hayashi, Y. Takahashi, K. Hirahata, Y. Imamura, H. Hase, C. Castledine, J. Gilg, C. Rogers, Y. Ben-Shlomo, F. Caskey, J. S. Sandhu, G. S. Bajwa, S. Kansal, J. Sandhu, A. Jayanti, M. Nikam, L. Ebah, A. Summers, S. Mitra, J. Agar, A. Perkins, R. Simmonds, A. Tjipto, S. Amet, V. Launay-Vacher, M. Laville, A. Tricotel, C. Frances, B. Stengel, J.-Y. Gauvrit, N. Grenier, G. Reinhardt, O. Clement, N. Janus, L. Rouillon, G. Choukroun, G. Deray, A. Bernasconi, R. Waisman, A. P. Montoya, A. A. Liste, R. Hermes, G. Muguerza, R. Heguilen, E. L. Iliescu, V. Martina, M. A. Rizzo, P. Magenta, L. Lubatti, G. Rombola, M. Gallieni, C. Loirat, H. Mellerio, M. Labeguerie, B. Andriss, E. Savoye, M. Lassale, C. Jacquelinet, C. Alberti, Y. Aggarwal, J. Baharani, S. Tabrizian, S. Ossareh, M. Zebarjadi, P. Azevedo, F. Travassos, I. Frade, M. Almeida, J. Queiros, F. Silva, A. Cabrita, R. Rodrigues, C. Couchoud, J. Kitty, S. Benedicte, C. Fergus, C. Cecile, B. Sahar, V. Emmanuel, J. Christian, E. Rene, H. Barahimi, M. Mahdavi-Mazdeh, M. Nafar, M. Petruzzi, M. De Benedittis, M. Sciancalepore, L. Gargano, P. Natale, M. C. Vecchio, V. Saglimbene, F. Pellegrini, G. Gentile, P. Stroumza, L. Frantzen, M. Leal, M. Torok, A. Bednarek, J. Dulawa, E. Celia, R. Gelfman, J. Hegbrant, C. Wollheim, S. Palmer, D. W. Johnson, P. J. Ford, J. C. Craig, G. F. Strippoli, M. Ruospo, B. El Hayek, B. Hayek, E. Baamonde, E. Bosch, J. I. Ramirez, G. Perez, A. Ramirez, A. Toledo, M. M. Lago, C. Garcia-Canton, M. D. Checa, B. Canaud, B. Lantz, A. Granger-Vallee, P. Lertdumrongluk, N. Molinari, J. Ethier, M. Jadoul, B. Gillespie, C. Bond, S. Wang, T. Alfieri, P. Braunhofer, B. Newsome, M. Wang, B. Bieber, M. Guidinger, L. Zuo, X. Yu, X. Yang, J. Qian, N. Chen, J. Albert, Y. Yan, S. Ramirez, M. Beresan, A. Lapidus, M. Canteli, A. Tong, B. Manns, J. Craig, G. Strippoli, M. Mortazavi, B. Vahdatpour, S. Shahidi, A. Ghasempour, D. Taheri, S. Dolatkhah, A. Emami Naieni, M. Ghassami, M. Khan, K. Abdulnabi, P. Pai, M. Vecchio, M. A. Muqueet, M. J. Hasan, M. A. Kashem, P. K. Dutta, F. X. Liu, L. Noe, T. Quock, N. Neil, G. Inglese, M. Motamed Najjar, B. Bahmani, A. Shafiabadi, J. Helve, M. Haapio, P.-H. Groop, C. Gronhagen-Riska, P. Finne, R. Sund, M. Cai, S. Baweja, A. Clements, A. Kent, R. Reilly, N. Taylor, S. Holt, L. Mcmahon, M. Carter, F. M. Van der Sande, J. Kooman, R. Malhotra, G. Ouellet, E. L. Penne, S. Thijssen, M. Etter, A. Tashman, A. Guinsburg, A. Grassmann, C. Barth, C. Marelli, D. Marcelli, G. Von Gersdorff, I. Bayh, L. Scatizzi, M. Lam, M. Schaller, T. Toffelmire, Y. Wang, P. Sheppard, L. Neri, V. A. Andreucci, L. A. Rocca-Rey, S. V. Bertoli, D. Brancaccio, G. De Berardis, G. Lucisano, D. Johnson, A. Nicolucci, C. Bonifati, S. D. Navaneethan, V. Montinaro, M. Zsom, A. Bednarek-Skublewska, G. Graziano, J. N. Ferrari, A. Santoro, A. Zucchelli, G. Triolo, S. Maffei, S. De Cosmo, V. M. Manfreda, L. Juillard, A. Rousset, F. Butel, S. Girardot-Seguin, T. Hannedouche, M. Isnard, Y. Berland, P. Vanhille, J.-P. Ortiz, G. Janin, P. Nicoud, M. Touam, E. Bruce, B. Grace, P. Clayton, A. Cass, S. Mcdonald, Y. Furumatsu, T. Kitamura, N. Fujii, S. Ogata, H. Nakamoto, K. Iseki, Y. Tsubakihara, C.-C. Chien, J.-J. Wang, J.-C. Hwang, H.-Y. Wang, W.-C. Kan, N. Kuster, L. Patrier, A.-S. Bargnoux, M. Morena, A.-M. Dupuy, S. Badiou, J.-P. Cristol, J.-M. Desmet, V. Fernandes, F. Collart, N. Spinogatti, J.-M. Pochet, M. Dratwa, E. Goffin, J. Nortier, D. S. Zilisteanu, M. Voiculescu, E. Rusu, C. Achim, R. Bobeica, S. Balanica, T. Atasie, S. Florence, S. Anne-Marie, L. Michel, C. Cyrille, A. Strakosha, N. Pasko, S. Kodra, N. Thereska, A. Lowney, E. Lowney, R. Grant, M. Murphy, L. Casserly, T. O' Brien, W. D. Plant, J. Radic, D. Ljutic, V. Kovacic, M. Radic, K. Dodig-Curkovic, M. Sain, I. Jelicic, T. Hamano, C. Nakano, S. Yonemoto, A. Okuno, M. Katayama, Y. Isaka, M. Nordio, A. Limido, M. Postorino, M. Nichelatti, M. Khil, I. Dudar, V. Khil, I. Shifris, M. Momtaz, A. R. Soliman, M. I. El Lawindi, P. Dzekova-Vidimliski, S. Pavleska-Kuzmanovska, I. Nikolov, G. Selim, T. Shoji, R. Kakiya, N. Tatsumi-Shimomura, Y. Tsujimoto, T. Tabata, H. Shima, K. Mori, S. Fukumoto, H. Tahara, H. Koyama, M. Emoto, E. Ishimura, Y. Nishizawa, and M. Inaba

Subjects
Transplantation, medicine.medical_specialty, Nephrology, business.industry, Epidemiology, Medicine, business, Intensive care medicine, Outcome (game theory)
Published
2012

16. AKI - Clinical

Author

E. Gok Oguz, R. Olmaz, K. Turgutalp, N. Muslu, M. A. Sungur, A. Kiykim, W. Van Biesen, J. Vanmassenhove, G. Glorieux, R. Vanholder, S. Chew, K. Forster, T. Kaufeld, J. Kielstein, T. Schilling, A. Haverich, H. Haller, B. Schmidt, P. Hu, X. Liang, Y. Chen, R. LI, F. Jiang, Z. LI, W. Shi, C. C. W. Lim, C. M. L. Chia, A. K. Tan, C. S. Tan, R. Ng, S. Subramani, A. Perez de Jose, C. Bernis Carro, R. Madero Jarabo, J. Bustamante, J. A. Sanchez Tomero, W. Chung, H. Ro, J. H. Chang, H. H. Lee, J. Y. Jung, L. Fazzari, A. Giuliani, J. Scrivano, L. Pettorini, U. Benedetto, R. Luciani, A. Roscitano, A. Napoletano, D. Coclite, E. Cordova, G. Punzo, R. Sinatra, P. Mene, N. Pirozzi, L. Shavit, R. Manilov, N. Algur, Y. Wiener-Well, I. Slotki, C. Pipili, C. S. Vrettou, K. Avrami, F. Economidou, K. Glynos, S. Ioannidou, V. Markaki, E. Douka, S. Nanas, A. De Pascalis, P. Cofano, S. Proia, A. Valletta, O. Vitale, F. Russo, E. Buongiorno, V. Filiopoulos, D. Biblaki, D. Lazarou, D. Chrysis, M. Fatourou, S. Lafoyianni, D. Vlassopoulos, O. Zakiyanov, V. Kriha, J. Vachek, J. Svarcova, T. Zima, V. Tesar, M. Kalousova, M. Kaushik, C. Ronco, D. Cruz, L. Zhang, W. Zhang, N. Chen, A. A. Ejaz, G. Kambhampati, N. Ejaz, B. Dass, V. Lapsia, A. A. Arif, A. Asmar, M. Shimada, M. Alsabbagh, R. Aiyer, R. Johnson, T.-H. Chen, C.-H. Chang, M.-Y. Chang, Y.-C. Tian, C.-C. Hung, J.-T. Fang, C.-W. Yang, Y.-C. Chen, V. Cantaluppi, A. D. Quercia, F. Figliolini, S. Giacalone, A. Pacitti, M. Gai, C. Guarena, G. Leonardi, L. Biancone, G. Camussi, G. P. Segoloni, M. De Cal, P. Lentini, A. Clementi, G. M. Virzi, E. Scalzotto, A. Lacquaniti, V. Donato, M. R. Fazio, S. Lucisano, V. Cernaro, R. Lupica, M. Buemi, I. Helvaci, E. Anik, M. Wani, D. I. Wani, D. M. A. Bhat, D. K. Banday, D. M. S. Najar, D. A. R. Reshi, D. N. A. Palla, P. Iglesias, T. Olea, C. Vega-Cabrera, M. Heras, M. A. Bajo, G. Del Peso, M. J. Arias, R. Selgas, J. J. Diez, E. Daher, P. L. Costa, E. N. S. Pereira, R. D. P. Santos, K. L. Abreu, G. Silva Junior, E. D. B. Pereira, M. Raimundo, S. Crichton, Y. Syed, J. Martin, C. Whiteley, D. Bennett, M. Ostermann, A. Gjyzari, N. Thereska, A. Koroshi, M. Barbullushi, S. Kodra, A. Idrizi, A. Strakosha, E. Petrela, J. Lemmich Smith, A. Klimenko, E. Tuykhmenev, S. Villevalde, Z. Kobalava, S. Avdoshina, E. Tyukhmenev, M. Efremovtseva, H. Hayashi, S. Suzuki, K. Kataoka, Y. Kondoh, H. Taniguchi, D. Sugiyama, K. Nishimura, W. Sato, S. Maruyama, S. Matsuo, Y. Yuzawa, D. Geraldine, F. Muriel, H. Alexandre, R. Eric, P. Fu, M. Pozzato, F. Ferrari, P. Cecere, P. Mesiano, A. Vallero, S. Livigni, F. Quarello, L. Hudier, O. Decaux, A. Haddj-Elmrabet, L. Mandart, M. Lino-Daniel, F. Bridoux, E. Renaudineau, T. Sawadogo, P. Le Pogamp, C. Vigneau, D. Famee, H. M. Koo, H. J. Oh, S. H. Han, K. H. Choi, S.-W. Kang, M. Mehdi, M. Nicolas, C. Mariat, P. Shah, V. B. Kute, A. Vanikar, M. Gumber, H. Patel, H. Trivedi, C. Manetos, S. Poulaki, E.-S. Tripodaki, A. Papastylianou, C. Routsi, K. Uchida, U. Kensuke, K. Yamagata, C. Saitou, M. Okada, G. Chita, M. Davies, Y. Veriawa, S. Naicker, P. Mukhopadhyay, D. Mukherjee, R. Mishra, M. Kar, D. Zickler, H. Wesselmann, R. Schindler, E. Gutierrez, J. Egido, A. Rubio-Navarro, I. Buendia, L. M. Blanco-Colio, O. Toldos, F. Manzarbeitia, A. De Lorenzo, R. Sanchez, M. Praga, J. A. Moreno, M. Y. Kim, N. R. Kang, H. R. Jang, J. E. Lee, W. Huh, Y.-G. Kim, D. J. Kim, S.-C. Hong, J.-S. Kim, H. Y. Oh, T. Okamoto, K. Kamata, S. Naito, H. Tazaki, S. Kan, L.-G. Anne-Kathrin, K. Matthias, T. Speer, L. Andreas, G. Heinrich, V. Thomas, A. Poppleton, F. Danilo, C.-F. Lai, V.-C. Wu, C.-C. Shiao, T.-M. Huang, K.-D. Wu, M. Bedford, C. Farmer, J. Irving, P. Stevens, F. Patera, F. Mattozzi, S. Battistoni, R. M. Fagugli, M. Y. Park, S. J. Choi, J. G. Kim, S. D. Hwang, H. Xie, H. Chen, S. Xu, Q. He, J. Liu, W. Hu, Z. Liu, M. Dalboni, R. Blaya, B. M. Quinto, R. Narciso, M. Oliveira, J. Monte, M. Durao, M. Cendoroglo, M. Batista, A. L. Hanemann, A. Liborio, A. Martins, M. C. C. Pinheiro, G. Meneses, R. De Paula Pessoa, M. Sousa, F. S. M. Bezerra, P. L. M. M. Albuquerque, J. B. Lima, C. B. Lima, M. D. S. B. Veras, T. Nemoto Matsui, C. Totoli, M. C. Cruz Andreoli, M. P. Vilela Coelho, N. K. Guimaraes de Souza, A. L. Ammirati, F. De Carvalho Barreto, B.-H. Ferraz Neto, B. Fortunato Cardoso Dos Santos, A. Abraham, G. Abraham, M. Mathew, P. M. A. Duarte, F. B. Duarte, E. M. Barros, F. Q. S. Castro, H. Palomba, I. Castro, S. R. Sousa, A. N. Jesus, T. Romano, E. Burdmann, L. Yu, S. H. Kwon, J. Y. You, Y. K. Hyun, S. A. Woo, J. S. Jeon, H. J. Noh, D. C. Han, L. Tozija, Z. Petronievic, G. Selim, I. Nikolov, O. Stojceva-Taneva, K. Cakalaroski, A. Lukasz, J. Beneke, J. Menne, M. Schiffer, N. Polanco, E. Hernandez, V. Gutierrez Millet, E. Gonzalez Monte, E. Morales, L. Francisco Javier, G.-F. Nuria, M.-G. Jose Maria, M. Bes Rastrollo, A. Angioi, M. Conti, R. Cao, A. Atzeni, G. Pili, V. Matta, E. Murgia, P. Melis, V. Binda, A. Pani, F. Thome, F. Leusin, E. Barros, C. Morsch, A. Balbinotto, C. Pilla, V. Premru, J. Buturovic-Ponikvar, R. Ponikvar, A. Marn-Pernat, B. Knap, J. Kovac, J. Gubensek, B. Kersnic, L. Krnjak, M. Prezelj, J. Granatova, M. Havrda, Z. Hruskova, K. Kratka, O. Remes, M. Mokrejsova, M. Bolkova, V. Lanska, I. Rychlik, M. D. Uniacke, R. J. Lewis, S. Harris, P. Roderick, N. Martin, K. Ulrich, B. Jan, B. Jorn, B. Reinhard, K. Jan, H. Hermann, F. Meyer Tobias, R. Leyla, M. W. Schmidt Bernhard, S. Harald, S. Jurgen, K. Tanja, S. Mario, E. Sang Hi, M. Claus, V. Frank, S. Aleksej, S. Sengul, S. Robert, W. Karin, G. Feikah, F. Menne Tobias, N. Meyer Tobias, G. Beutel, S. Fleig, J. Steinhoff, T. Meyer, C. Hafer, J. Bramstedt, V. Busch, M. Vischedyk, U. Kuhlmann, W. Ries, S. Mitzner, S. Mees, S. Stracke, J. Nurnberger, P. Gerke, M. Wiesner, B. Sucke, M. Abu-Tair, A. Kribben, N. Klause, F. Merkel, S. Schnatter, E. Dorresteijn, O. Samuelsson, R. Brunkhorst, G. Stec-Hus Registry, A. Reising, F.-C. Bange, M. Hiss, F. Vetter, S. M. Bode-Boger, J. Martens-Lobenhoffer, B. M. W. Schmidt, J. T. Kielstein, H. S. Shin, Y. S. Jung, and H. Rim

Subjects
Transplantation, Nephrology
Published
2012

17. Mineral and bone disease - CKD 5D

Author

M. Hecking, A. Kainz, B. Bielesz, M. Plischke, G. Beilhack, W. H. Hoerl, G. Sunder-Plassmann, C. Bieglmayer, S. Benchetrit, J. Green, J. Bernheim, E. Golan, N. Oyake, K. Suzuki, S. Itoh, K. Tanabe, A. Fujimori, S. Okada, K. Yamamoto, M. Sakai, N. Kamiura, P. Solenne, F. Guebre-Egziabher, J. Bacchetta, J. Drai, M. Richard, R. Chapurlat, D. Fouque, Z. Nowak, K. Grzegorz, K. Maria, W. Zofia, K. Zamboch, J. Zahalkova, Z. Kosatikova, P. Skypalova, J. Skarda, J. Cunha, M. Boim, V. Ferreira, M. Naves, H. Kikuchi, H. Shimada, Y. Takimoto, R. Karasawa, M. Shimotori, K. Ikarashi, N. Saito, S. Miyazaki, S. Sakai, M. Suzuki, H. Ogata, A. Takeshima, M. Yamamoto, K. Asakura, T. Kato, K. Shishido, F. Koiwa, M. Mizobuchi, E. Kinugasa, T. Akizawa, F. Londrino, V. Corbani, M. Ardini, V. Falqui, T. Zattera, G. Rombola', Y. Takeshige, K. Matsuzaka, P. Ciceri, E. Volpi, I. Brenna, F. Elli, E. Borghi, D. Brancaccio, M. Cozzolino, K. Farrand, J. B. Copley, J. Heise, M. Fridman, M. Keith, A. Silverberg, R. Wilson, L. Poole, G. Jean, E. Bresson, C. Chazot, F. Maduell, M. Arias, A. Sentis, N. Rodriguez, S. Jimenez, B. Alemany, N. Perez, M. Vera, N. Fontsere, M. Carrera, A. Cases, M. Sonikian, T. Miha, I. Skarakis, I. Karatzas, A. Karaitianou, V. Tomanoski, D. Petkovic, I. Curic, R. Hrvacevic, N. Kaperonis, C. Kourvelou, A. Sgantzos, D. Nastou, G. Ntatsis, S. Ziakka, F. Karakasis, V. Nikolopoulos, D. Zoubaniotou, A. Koutsovasili, A. Zagorianakos, V. Kolovos, N. Papagalanis, V. Forni, M. Pruijm, E. Tousset, C. Zweiacker, I. Menetrey, L. Berwert, R. Bullani, A. Cherpillod, L. Gabutti, T. Gauthier, G. Halabi, C. Mathieu, P. Meier, O. Phan, S. Pianca, C. Schoenholzer, D. Teta, B. Von Albertini, B. Vrijens, M. Burnier, N. Kurita, M. Fukagawa, Y. Onishi, T. Yamaguchi, T. Hasegawa, S. Fukuma, K. Kurokawa, S. Fukuhara, P. Urena, I. Bridges, C. Christiano, S. Cournoyer, K. Cooper, M. Farouk, N. Kopyt, M. Rodriguez, D. Zehnder, A. Covic, Y. Tominaga, T. Hiramitsu, T. Yamamoto, K. Nanmoku, Y. Matsuda, T. Tsuzuki, C.-L. Lang, K.-C. Lu, M.-H. Wang, S.-Y. Liu, J.-W. Huang, C.-K. Chiang, K.-Y. Hung, C. Bantis, N.-M. Kouri, E. Tsandekidou, S. Frangidis, A. Tsiandoulas, E. Liakou, G. Bamichas, M. Stangou, A. Papagianni, G. Efstratiadis, T. Natse, D. Memmos, P. Messa, G. Cannella, S. Mazzaferro, X. Yu, B. Bieber, M. Guidinger, X. Yang, F. Tentori, R. Pisoni, J. Qian, N. Chen, Y. Yan, M. Wang, L. Zuo, H. Wang, J. Albert, S. Ramirez, F. Caccetta, M. Caroppo, F. Musio, A. Mudoni, A. Accogli, M. D. Zacheo, V. Nuzzo, G. Selim, O. Stojceva-Taneva, L. Tozija, S. Gelev, V. Pusevski, P. Dzekova-Vidimliski, I. Rambabova-Busletic, A. Sikole, P. Esposito, R. Coppo, F. Malberti, A. Dal Canton, K. Moriwaki, H. Komaba, T. Kakuta, V. Cernaro, R. Lupica, V. Donato, A. Lacquaniti, M. R. Fazio, S. Lucisano, M. Buemi, S. Okuno, E. Ishimura, N. Tsuboniwa, K. Norimine, K. Yamakawa, T. Yamakawa, S. Shoji, K. Mori, Y. Nishizawa, M. Inaba, M. Dahaba, S. Seck, M. Cisse, Y. Jotoku, Y. Sato, N. Dimkovic, E. Asicioglu, A. Kahveci, H. Arikan, M. Koc, S. Tuglular, C. Ozener, R. Kido, T. Yamaguch, A. Krasniak, M. Drozdz, G. Chmiel, P. Podolec, M. Pasowicz, M. Kowalczyk-Michalek, W. Sulowicz, G. Perez-Suarez, E. Baamonde, E. Bosch, J. I. Ramirez, B. El Hayek, M. D. M. Lago, C. Garcia, M. D. Checa, R. Hiramatsu, Y. Ubara, K. Salas, E. S. Vicent, J. C. Gonzalez Oliva, M. Fulquet, V. Duarte, M. Pou, A. Saurina, J. Macias, M. Ramirez de Arellano, P. Matias, C. Jorge, M. Mendes, T. Amaral, C. Ferreira, I. Aires, C. Gil, A. Ferreira, C. Arcal, J. M. Campistol, S. Seferi, M. Rroji, E. Likaj, E. Petrela, M. Barbullushi, N. Zeneli, S. Mumajesi, N. Thereska, C. Vulpio, M. Bossola, E. Stigliano, G. Fadda, A. P. S. Gueiros, J. O. Borba Junior, A. B. d. M. D. S. Lordsllen, J. E. d. B. Gueiros, N. Itami, K. Tuneyama, S. Uemura, H. Hamada, J. Takada, K. Takahashi, K. Adamidis, T. Apostolou, C. Pleros, T. Oikonomaki, E. Kyratzi, D. Exarchos, G. Metaxatos, S. Dracopoulos, N. Nikolopoulou, P. Delanaye, B. Dubois, J.-M. Krzesinski, E. Cavalier, V. De la Fuente, M. T. Gil, P. Gutierrez, P. Delgado, J. Ribero, L. Arenas, S. Sezer, E. Tutal, Z. Bal, M. Erkmen Uyar, F. N. Ozdemir Acar, R. Azevedo de Oliveira, F. Carvalho Barreto, L. Dos Reis, J. Cunha Ferreira, Z. Maria Leme Britto, R. Maria Moyses, V. Jorgetti, R. Ozelsancak, B. Gurlek Demirci, D. Torun, L. Veljancic, M. Radojevic, Z. Paunic, N. Vavic, K. Obrencevic, Z. Kovacevic, and J. Pejovic

Subjects
Transplantation, Nephrology
Published
2012

18. Clinical Nephrology - Epidemiology II

Author

H. Agnes, P. Kalman, A. Jozsef, B. Henrik, I. Mucsi, K. Kamata, T. Sano, S. Naito, T. Okamoto, C. Okina, M. Kamata, J. Murano, K. Kobayashi, M. Uchida, T. Aoyama, Y. Takeuchi, Y. Nagaba, H. Sakamoto, C. Torino, V. Panuccio, A. Clementi, M. Garozzo, G. Bonanno, R. Boito, G. Natale, T. Cicchetti, A. Chippari, D. Logozzo, G. Alati, S. Cassani, A. Sellaro, G. D'arrigo, G. Tripepi, A. Roberta, M. Postorino, F. Mallamaci, C. Zoccali, E. Buonanno, S. Brancaccio, V. Fimiani, P. Napolitano, R. Spadola, L. Morrone, B. DI Iorio, D. Russo, A. Betriu, M. Martinez-Alonso, T. Vidal, J. Valdivielso, E. Fernandez, F. Bernadette, B. Jean-Baptiste, L. Frimat, N. D. Madala, G. P. Thusi, N. Sibisi, B. G. Mazibuko, A. G. H. Assounga, N.-C. Tsai, H.-H. Wang, Y.-C. Chen, C.-C. Hung, S.-J. Hwang, H.-C. Chen, P. Branco, T. Adragao, R. Birne, A. R. Martins, R. Vizinho, A. Gaspar, M. J. Grilo, J. D. Barata, D. Bonhorst, P. Adragao, J. S. Kim, J. W. Yang, M. K. Kim, S. O. Choi, B. G. Han, N. Nathalie, E. Sunny, G. Glorieux, B. Daniela, B. Fellype, L. Sophie, L. Horst D, M. Ziad, V. Raymond, M. Yanai, K. Okada, K. Takeuchi, K. Nitta, S. Takahashi, M. Morena, I. Jaussent, A. Halkovich, A.-M. Dupuy, A.-S. Bargnoux, L. Chenine, H. Leray-Moragues, K. Klouche, H. Vernhet, B. Canaud, J.-P. Cristol, A. Shutov, V. Serov, J. Kuznetsova, M. Menzorov, D. Serova, L. Petrescu, A. Zugravu, C. Capusa, S. Stancu, S. Cinca, C. Anghel, D. Timofte, L. Medrihan, D. Ionescu, G. Mircescu, T.-W. Hsu, K.-L. Kuo, S.-C. Hung, D.-C. Tarng, S. Lee, I. Kim, D. Lee, H. Rhee, S. Song, E. Seong, I. Kwak, M. Holzmann, C. Gardell, A. Jeppsson, U. Sartipy, Y. Solak, M. I. Yilmaz, K. Caglar, M. Saglam, H. Yaman, A. Sonmez, H. U. Unal, M. Gok, A. Gaipov, M. Kayrak, T. Eyileten, S. Turk, A. Vural, L. DI Lullo, F. Floccari, R. Rivera, A. Granata, A. D'amelio, F. Logias, G. Otranto, M. Malaguti, A. Santoboni, F. Fiorini, T. Connor, D. Oygar, D. Nitsch, D. Gale, R. Steenkamp, G. H. Neild, P. Maxwell, I. Louise Hogsbro, B. Redal-Baigorri, B. Sautenet, J. M. Halimi, A. Caille, P. Goupille, B. Giraudeau, Y. Oguz, M. Yenicesu, H. Cetinkaya, Y. Ishimoto, T. Ohki, M. Sugahara, T. Kanemitsu, M. Kobayashi, L. Uchida, N. Kotera, S. Tanaka, T. Sugimoto, N. Mise, N. Miyazaki, J. Matsumoto, I. Murata, G. Yoshida, K. Morishita, H. Ushikoshi, K. Nishigaki, S. Ogura, S. Minatoguchi, R. Harvey, A. Ala, D. Banerjee, C. Farmer, J. Irving, H. Hobbs, T. Wheeler, B. Klebe, P. Stevens, G. Selim, O. Stojceva-Taneva, L. Tozija, N. Stojcev, S. Gelev, P. Dzekova-Vidimliski, S. Pavleska, A. Sikole, A. R. Qureshi, M. Evans, M. Stendahl, K. G. Prutz, C. G. Elinder, K. Tamagaki, H. Kado, M. Nakata, T. Kitani, N. Ota, R. Ishida, E. Matsuoka, Y. Shiotsu, M. Ishida, Y. Mori, M. Christelle, N. Rognant, D. Evelyne, F. Sophie, J. Laurent, L. Maurice, R. Silverwood, M. Pierce, D. Kuh, C. Savage, C. Ferro, D. G. Moniek, M. De Goeij, H. Nynke, O. Gurbey, R. Joris, D. Friedo, P. Clayton, B. Grace, A. Cass, S. Mcdonald, V. Lorenzo, M. Martin Conde, A. Dusso, J. M. Valdivielso, D. P. Roggeri, G. Cannella, M. Cozzolino, S. Mazzaferro, P. Messa, D. Brancaccio, R. De Souza Faria, N. Fernandes, J. Lovisi, M. Moura Marta, M. Reboredo, B. Do Vale Pinheiro, M. Bastos, F. Hundt, S. Pabst, C. Hammerstingl, T. Gerhardt, D. Skowasch, R. Woitas, A. A. Lopes, L. F. Silva, C. M. Matos, M. S. Martins, F. A. Silva, G. B. Lopes, F. Pizzarelli, P. Dattolo, S. Michelassi, C. Rossi, S. Bandinelli, M. Mieth, R. Mass, L. Ferrucci, S. Parisi, S. Arduino, R. Attini, F. Fassio, M. Biolcati, A. Pagano, C. Bossotti, M. Ferraresi, P. Gaglioti, T. Todros, G. B. Piccoli, T. M. Salgado, B. Arguello, S. I. Benrimoj, F. Fernandez-Llimos, P. Bailey, C. Tomson, Y. Ben-Shlomo, A. Santoro, P. Rucci, M. Mandreoli, F. Caruso, M. Corradini, M. Flachi, D. Gibertoni, A. Rigotti, G. Russo, M. Fantini, H. S. Mahapatra, S. Choudhury, G. Buxi, N. Sharma, Y. Gupta, V. Sekhar, N. Yanagisawa, M. Ando, A. Ajisawa, K. Tsuchiya, O. Janusz, M. Mikolaj, M. Jacek, R. Boleslaw, S. Prakash, R. Coffin, J. Schold, D. Einstadter, S. Stark, D. Rodgers, M. Howard, A. Sehgal, S. Palmer, A. Tong, B. Manns, J. Craig, M. Ruospo, L. Gargano, G. Strippoli, M. Vecchio, M. Petruzzi, M. De Benedictis, F. Pellegrini, Y. Ohno, E. Ishimura, T. Naganuma, K. Kondo, W. Fukushima, K. Mui, M. Inaba, Y. Hirota, X. Sun, S. Jiang, H. Gu, Y. Chen, C. XI, X. Qiao, X. Chen, E. Daher, G. S. Junior, C. N. Jacinto, R. S. Pimentel, G. B. R. Aguiar, C. B. Lima, R. C. Borges, L. P. C. Mota, J. V. L. Melo, S. A. Melo, V. T. Canamary, M. Alves, S. M. H. A. Araujo, Y. K. Huang, K. Rogacev, B. Cremers, A. Zawada, S. Seiler, N. Binder, P. Ege, G. Grosse-Dunker, I. Heisel, F. Hornof, J. Jeken, N. Rebling, C. Ulrich, B. Scheller, M. Bohm, D. Fliser, G. H. Heine, B. Robinson, M. Wang, B. Bieber, R. Fluck, P. G. Kerr, B. Wikstrom, M. Krishnan, A. Nissenson, R. L. Pisoni, S. Mykleset, T. B. Osthus, B. Waldum, I. Os, J. Buttigieg, A. Cassar, J. Farrugia Agius, M. Hara, M. Yamato, K. Yasuda, and K. Sasaki

Subjects
Transplantation, medicine.medical_specialty, Acute coronary syndrome, business.industry, Red blood cell distribution width, medicine.disease, Sudden death, Uremia, Nephrology, Diabetes mellitus, Internal medicine, Heart failure, medicine, Cardiology, Endothelial dysfunction, business, Kidney disease
Published
2012

19. Cardiovascular complications in CKD 5D

Author

M. Fusaro, M. Noale, G. Tripepi, A. D'angelo, D. Miozzo, M. Gallieni, P.-V. Study Group, M. Tsamelesvili, C. Dimitriadis, A. Papagianni, C. Raidis, G. Efstratiadis, D. Memmos, R. Mutluay, C. Konca Degertekin, U. Derici, S. M. Deger, F. Akkiyal, S. Gultekin, S. Gonen, G. Tacoy, T. Arinsoy, S. Sindel, C. Sanchez-Perales, E. Vazquez, E. Merino, P. Perez Del Barrio, F. J. Borrego, M. J. Borrego, A. Liebana, M. Krzanowski, K. Janda, P. Dumnicka, A. Krasniak, W. Sulowicz, Y.-O. Kim, S.-A. Yoon, Y.-S. Yun, H.-C. Song, B.-S. Kim, M. A. Cheong, A. Pasch, S. Farese, J. Floege, W. Jahnen-Dechent, T. Ohtake, R. Furuya, M. Iwagami, D. Tsutsumi, Y. Mochida, K. Ishioka, M. Oka, K. Maesato, H. Moriya, S. Hidaka, S. Kobayashi, A. Guedes, A. Malho Guedes, A. Pinho, A. Fragoso, A. Cruz, P. Mendes, E. Morgado, I. Bexiga, A. P. Silva, P. Neves, N. Oyake, K. Suzuki, S. Itoh, S. Yano, K. Turkmen, H. Kayikcioglu, O. Ozbek, M. Saglam, A. Toker, H. Z. Tonbul, S. Gelev, L. Trajceska, E. Srbinovska, S. Pavleska, V. Amitov, G. Selim, P. Dzekova, A. Sikole, H. Bouarich, S. Lopez, C. Alvarez, I. Arribas, P. DE Sequera, D. Rodriguez, S. Tanaka, T. Kanemitsu, M. Sugahara, M. Kobayashi, L. Uchida, Y. Ishimoto, N. Kotera, S. Tanimoto, K. Tanabe, K. Hara, T. Sugimoto, N. Mise, B. Goldstein, M. Turakhia, C. Arce, W. Winkelmayer, B. E.-D. Zayed, K. Said, M. Nishimura, Y. Okamoto, T. Tokoro, M. Nishida, T. Hashimoto, N. Iwamoto, H. Takahashi, T. Ono, N. Sato, J. Raimann, L. A. Usvyat, J. Sands, N. W. Levin, P. Kotanko, M. Iwasaki, N. Joki, Y. Tanaka, N. Ikeda, T. Hayashi, S. Kubo, T.-A. Imamura, Y. Takahashi, K. Hirahata, Y. Imamura, H. Hase, K. Claes, B. Meijers, B. Bammens, D. Kuypers, M. Naesens, Y. Vanrenterghem, P. Evenepoel, G. Boscutti, L. Calabresi, M. Bosco, S. Simonelli, E. Boer, C. Vitali, M. Martone, P. L. Mattei, G. Franceschini, E. Baligh, E. El-Shafey, A. Ezaat, A. Zawada, K. Rogacev, B. Hummel, O. Grun, A. Friedrich, B. Rotter, P. Winter, J. Geisel, D. Fliser, G. H. Heine, J.-I. Makino, K.-S. Makino, T. Ito, S. Genovesi, A. Santoro, P. Fabbrini, E. Rossi, D. Pogliani, A. Stella, G. Bonforte, G. Remuzzi, S. Bertoli, C. Pozzi, S. Pasquali, L. Cagnoli, F. Conte, I. Buzadzic, J. Tosic, N. Dimkovic, Z. Djuric, J. Popovic, I. Pejin Grubisa, N. Barjaktarevic, A. DI Napoli, D. DI Lallo, M. F. Salvatori, F. Franco, S. Chicca, G. Guasticchi, M. Onofriescu, S. Hogas, V. Luminita, A. Mugurel, V. Gabriel, F. Laura, M. Irina, C. Adrian, E. Bosch, E. Baamonde, C. Culebras, G. Perez, B. El Hayek, J. I. Ramirez, A. Ramirez, C. Garcia, M. Lago, A. Toledo, M. D. Checa, T. Taira, T. Hirano, K. Nohtomi, T. Hyodo, T. Chiba, A. Saito, Y. K. Kim, E. J. Choi, C. W. Yang, Y.-S. Kim, P. S. Lim, W. Ming Ying, J. Ya-Chung, I. Zaripova, I. Kayukov, A. Essaian, A. Nimgirova, H. Young, M. Dungey, E. L. Watson, R. Baines, J. O. Burton, A. C. Smith, K. Yamazaki, M. Bossola, L. Colacicco, D. Scribano, C. Vulpio, L. Tazza, T. Okada, N. Okada, I. Michibata, T. Yura, N. Montero, M. Soler, M. Pascual, C. Barrios, E. Marquez, E. Rodriguez, M. A. Orfila, H. Cao, E. Arcos, J. Comas, J. Pascual, M. Ferrario, F. Garzotto, T. Sironi, S. Monacizzo, F. Basso, D. N. Cruz, U. Moissl, C. Tetta, M. G. Signorini, S. Cerutti, C. Ronco, I. Mostovaya, M. Grooteman, M. Van den Dorpel, L. Penne, N. Van der Weerd, A. Mazairac, C. Den Hoedt, R. Levesque, M. Nube, P. Ter Wee, M. Bots, P. Blankestijn, J. Liu, K. L. MA, X. Zhang, B. C. Liu, I.-D. Vladu, R. Mustafa, D. Cana-Ruiu, C. Vaduva, C. Grauntanu, E. Mota, R. Singh, N. Abbasian, C. Stover, N. Brunskill, J. Burton, K. Herbert, A. Bevington, M. Wu, R.-N. Tang, M. Gao, H. Liu, L. Chen, L.-L. LV, B.-C. Liu, M. Nikodimopoulou, S. Liakos, S. Kapoulas, C. Karvounis, D. Fedak, M. Kuzniewski, D. Paulina, B. Kusnierz-Cabala, M. Kapusta, B. Solnica, A. Junque, E. S. Vicent, L. Moreno, M. Fulquet, V. Duarte, A. Saurina, M. Pou, J. Macias, M. Lavado, M. Ramirez de Arellano, M. Ryuzaki, H. Nakamoto, S. Kinoshita, E. Kobayashi, C. Takimoto, T. Shishido, G. Enia, C. Torino, R. Tripepi, V. Panuccio, M. Postorino, A. Clementi, M. Garozzo, G. Bonanno, R. Boito, G. Natale, T. Cicchetti, A. Chippari, D. Logozzo, G. Alati, S. Cassani, A. Sellaro, C. Zoccali, B. Quiroga, E. Verde, S. Abad, A. Vega, M. Goicoechea, J. Reque, J. M. Lopez-Gomez, J. Luno, C. Cabre Menendez, V. Moles, J. P. Vives, D. Villa, J. Vinas, T. Compte, M. Arruche, C. Diaz, J. Soler, J. Aguilera, A. Martinez Vea, A. De Mauri, P. David, M. M. Conte, D. Chiarinotti, C. E. Ruva, M. De Leo, A.-S. Bargnoux, M. Morena, I. Jaussent, L. Chalabi, P. Bories, J.-J. Dion, P. Henri, M. Delage, A.-M. Dupuy, S. Badiou, B. Canaud, J.-P. Cristol, E. Sironi, F. Pieruzzi, E. Galbiati, M. R. Vigano, S. Anpalakhan, S. Rocha, N. Chitalia, R. Sharma, J. C. Kaski, J. Chambers, D. Goldsmith, D. Banerjee, V. Cernaro, A. Lacquaniti, R. Lupica, S. Lucisano, M. R. Fazio, V. Donato, M. Buemi, I. Segalen, U. Vinsonneau, T. Tanquerel, G. Quiniou, Y. Le Meur, E. Seibert, M. Girndt, K. Zohles, C. Ulrich, A. Kluttig, S. Nuding, C. Swenne, J. Kors, K. Werdan, R. Fiedler, N. C. Van der Weerd, M. P. Grooteman, M. A. Van den Dorpel, M. J. Nube, J. Wetzels, D. W. Swinkels, P. M. Ter Wee, A. Khandekar, J. Khandge, J. E. Lee, S. J. Moon, K. H. Choi, H. Y. Lee, B. S. Kim, E. Tuaillon, A. Rodriguez, L. Chenine, J.-P. Vendrell, Y.-M. Sue, C.-H. Tang, Y.-C. Chen, P. Segura, M. J. Garcia Cortes, J. M. Gil, M. M. Biechy, D. Poulikakos, A. Shah, M. Persson, P. Dattolo, M. Amidone, S. Michelassi, L. Moriconi, G. Betti, P. Conti, A. Rosati, A. Mannarino, V. Panichi, F. Pizzarelli, K. Klejna, B. Naumnik, E. Koc-Zorawska, M. Mysliwiec, S. Dimitrie, H. Simona, O. Mihaela, O. Gabriela, S. Radu, P. Octavian, H. Akdam, H. Akar, Y. Yenicerioglu, O. Kucuk, I. Kurt Omurlu, S. Thambiah, R. Roplekar, P. Manghat, I. Fogelman, W. Fraser, G. Hampson, E. Likaj, G. Caco, S. Seferi, M. Rroji, M. Barbullushi, N. Thereska, A. Serban, V. Carmen, S. Cristian, L. Silvia, and A. Covic

Subjects
Transplantation, medicine.medical_specialty, Nephrology, business.industry, medicine, Intensive care medicine, business
Published
2012

20. Pathophysiology CKD 5D

Author

M. Adamczak, A. Wiecek, L. Nowak, A. E. Grzegorzewska, L. Niepolski, D. Pajzderski, W. A. A. A. Mohamed, F. M. Khamis Zaki, W. H. M. Bekhit, I. S. Sherif, C.-C. Lin, H.-Y. Chen, Y.-L. Chiu, S.-P. Hsu, M.-F. Pai, J.-Y. Yang, Y.-S. Peng, T.-J. Tsai, K.-D. Wu, S. Shojai, U. Udayaraj, P. Shojai, R. Zwiech, A. Bruzda-Zwiech, K. Musial, D. Zwolinska, W. Piotr M., A. Mostowska, P. P. Jagodzinski, V. Ortalda, P. Tomei, T. Yabarek, O. Tobaldini, C. Gangemi, M. G. Messa, A. Lupo, L. Ebah, M. Nikam, A. Summers, I. Dawidowska, A. Jayanti, H. Wiig, P. Brenchley, S. Mitra, S. Mikami, T. Hamano, O. Iba, M. Toki, H. Mikami, Y. Takamitsu, M. Fujii, P. Dzekova-Vidimliski, A. Sikole, S. Gelev, G. Selim, L. Trajceska, S. Fujimoto, H. Inagaki, K. Fukudome, F. Ebihara, N. Yokota, Y. Sato, T. Akiba, S. Otsubo, K. Nitta, A. Rydzewska-Rosolowska, J. Gozdzikiewicz, J. Borawski, T. Hryszko, E. Koc-Zorawska, M. Mysliwiec, M. Arias, E. Banon-Maneus, A. Sole, N. Hierro-Garcia, J. Rovira, M. J. Ramirez-Bajo, L. F. Quintana, F. Diekmann, D. Moya-Rull, F. Maduell, J. M. Campistol, M. Erkmen Uyar, S. K. Toprak, H. Saglam, E. Tutal, M. Bay, O. Ilhan, S. Sezer, J. Malyszko, P. Kozminski, and E. Zbroch

Subjects
Transplantation, medicine.medical_specialty, Nephrology, business.industry, Medicine, business, Intensive care medicine, Pathophysiology
Published
2012

21. Aminotransferase activity as a poor predictor of liver disease progression in dialysis patients with chronic hepatitis C

Author

P, Dzekova-Vidimliski, G, Severova-Andreevska, L, Trajceska, V, Pusevski, G, Selim, S, Gelev, V, Amitov, S, Dzikova, and A, Sikole

Subjects
Male, Genotype, Liver, Renal Dialysis, Disease Progression, Humans, Alanine Transaminase, Female, Hepacivirus, Hepatitis C, Chronic, Middle Aged, Ultrasonography
Abstract

Lower aminotransferase activity in dialysis patients makes the assessment of the natural history of hepatitis C virus (HCV) infection difficult. The aim of the study was to determine the risk factors associated with the aminotransferase activity in dialysis patients with chronic hepatitis C. According to the serum levels of alanine aminotransferase (ALT) during the follow-up, the patients were divided in the two groups. The first group consisted of 34 chronically HCV infected patients with persistently normal levels of ALT. The second group included 46 chronically HCV infected patients with elevated levels of ALT. Genotype 1 was the dominant genotype in both groups (78 patients, 97.5%). Patients with the elevated ALT levels were characterized with a significantly shorter dialysis duration (p = 0.048) and a significantly shorter duration of HCV infection (p = 0.005) compared to the patients with persistently normal levels of ALT. The values of measured ultrasound parameters were not significantly different between the two groups. The univariate analysis identified a higher serum level of direct bilirubin (p = 0.044), shorter duration of dialysis (p=0.048), and shorter duration of HCV infection (p = 0.005) as potential predictors of elevated serum ALT levels in dialysis patients. After a stepwise logistic regression, none of the potential predictors was independently associated with the elevated ALT levels. Serum aminotransferase levels are poor predictors of liver disease progression in dialysis patients with chronic hepatitis C. Further studies should be conducted in order to identify non-invasive indicators of the disease progression in uremic patients with hepatitis C (Tab. 3, Ref. 22).

Published
2011

22. Diabetics on dialysis in the Republic of Macedonia: A nationwide epidemiological study

Author

M, Polenakovic, A, Sikole, I G, Nikolov, D, Georgiev, G, Selim, P, Dzekova-Vidimliski, S, Gelev, V, Amitov, A, Oncevski, G, Severova, S, Pavleska, A, Poposki, V, Kovaceska, M, Alceva, V, Zdravkovska, R, Antararov, S, Dimitrov, P, Janakievska, M, Damjanovski, E, Karceva Sarajlija, B, Velinova, K, Ivanovski, B, Panova, J, Neskovski, D, Jovcevski, M, Zafiroska, R, Mat, R, Filipovik, L, Sela, and K, Lamova

Subjects
Male, Renal Dialysis, Humans, Diabetic Nephropathies, Female, Middle Aged, Ambulatory Care Facilities, Republic of North Macedonia, Aged
Abstract

Incidence increase of diabetes mellitus (DM) has taken epidemic proportions in the world. Diabetic nephropathy (DN) is a most serious complication, taking a leading place as a factor in the progression of chronic kidney disease (CKD). Dialysis treatment of these patients is complex, expensive, and exerts an excessive burden on the health budgets of the affected countries.We performed a nationwide precise observational study with the aim of analysing diabetics on dialysis in dialysis centres throughout the Republic of Macedonia (RM) in 2002 and in 2006; to compare the results from patients records; and to gather data on the epidemiology, clinical characteristics and complications of diabetes type 1 (DM1) and diabetes type 2 (DM2).The prevalence of HD patients in RM was 1114 vs 1074 in 2002 and 2006, respectively. Of these, 109 (9.78%) vs. 115 (10.71%) had DM in 2002 and 2006, respectively. The percentage of diabetics on dialysis between different centers varied between 3% to 21% vs. 2.4% to 22.07% in 2002 and 2006, respectively. The mean age of the patients was 58+/-10.29 vs. 56.5+/-10.71 in 2002 and 2006, respectively. Patients with DM1 were 19 (17.43%) vs. 15 (13.04%) and with DM2 were 90 (82.57%) vs. 100 (86.96%) in 2002 and 2006, respectively. 28 (25.68%) vs. 31 (26.96%) patients were on oral anti-diabetic drugs and 62 (57.21%) vs. 69 (60%) patients were on insulin in 2002 and 2006, respectively. Mean age of DM1 patients was 47+/-11.6 y. vs. 45+/-7.32 y. respectively and of DM2 was 60.37+/-8.33 y. vs. 61.14+/-10.23 y., in 2002 and 2006, respectively. Mean time of insulin treatment was 9.5+/-6.63 y. vs. 10.85+/-9.29 y. in 2002 and 2006. Mean Body Mass Index (BMI) was 26.4 vs. 23.49+/-4.74 kg/m2 in DM1 and 25.5 vs. 24.77+/-3.70 kg/m2 in DM2 patients in 2002 and 2006, respectively. Thrombosis of first arteriovenous fistulae (AVF) occurred in 41% vs. 25.22% in 2002 and 2006, respecttitvely. Hepatitis C virus (HCV) infection was confirmed in 57% vs. 44% of DM patients in 2002 and 2006, respectively. Most common co-morbidity in patients was hypertension, 91% vs. 80.87% in 2002 and 2006, respectively.The number of diabetics on dialysis in the Republic of Macedonia did not increase in the period from 2002 to 2006. In DM2 diabetics on dialysis the frequency of complications is higher and time on dialysis is shorter than in DM1 patients. Early detection of diabetic nephropathy by primary care physicians as well as collaborative treatment by diabetologists, nephrologists, cardiologists and ophthalmologists before and during dialysis are important for improvement of treatment and survival of diabetic patients on dialysis.

Published
2010

23. Antibiotics for ventilator-associated pneumonia

Author

George Balalis, Mieke L van Driel, Adrian G Selim, and Balu Bhaskar

Subjects
Protocol (science), medicine.medical_specialty, medicine.drug_class, business.industry, Antibiotics, medicine, Ventilator-associated pneumonia, Intensive care medicine, medicine.disease, business
Published
2010

24. Effect of nephrology referral on the initiation of haemodyalisis and mortality in ESRD patients

Author

G, Selim, O, Stojceva-Taneva, M, Polenakovic, Lj, Georgievska-Ismail, S, Gelev, E, Hristova-Antova, V, Andova, P, Dzekova, and A, Sikole

Subjects
Adult, Aged, 80 and over, Male, Adolescent, Renal Dialysis, Humans, Kidney Failure, Chronic, Female, Middle Aged, Referral and Consultation, Aged
Abstract

Late nephrology referral of patients with chronic kidney disease (CKD) has been suggested as increasing mortality after the initiation of dialysis. The aim of this study was to assess the impact of nephrology referral on the initiation of haemodyalisis (HD) and mortality during HD treatment in end-stage renal disease (ESRD) patients who have died in our institution over a five-year period. We studied data from all 117 patients on HD treatment in our institution who died (after 90 days of HD treatment) in the period between 01.01. 2002 and 31.12. 2006. Early (ER) and late referral (LR) were defined by the time of follow-up by a nephrologist greater than or less than 6 months, respectively, before the initiation of haemodialysis. Out of a total of 117 patients, 37.6% (44 patients) started HD in the ER group and 62.4% (73 patients) in the LR group. At the start of HD, LR patients were older, had a higher proportion of temporary catheters and had a significantly lower levels of haemoglobin and diuresis. Creatinine clearance was less in the LR (7.67 +/- 3.86 ml/min/1.73 m2) vs. the ER group (8.70 +/- 3.62 ml/min/1.73 m2), but not significantly different. Cardiovascular disease (CVD), defined by a history of myocardial infarction, cerebral vascular disease, peripheral arteriopathy, and/or heart failure, was also significantly more common among LR patients compared to ER (56%; 27%, p = 0.002). During the haemodyalisis treatment, the LR group had significantly lower levels of haemoglobin and haematocrit. CVD accounted for about 64% of deaths observed in the LR group. According to echocardiography data, there were no significant differences in the left ventricular mass index (LVMI) between the LR and ER groups at the time of dialysis initiation, but during haemodialysis treatment the LR group had significantly greater LVMI than the ER group (232,96 +/- 92,48 g/m2 vs.184,09 +/- 51,74 g/m2; p = 0,031). The time until death in months during dialysis treatment was significantly different between the LR and ER group, (69.51 +/- 64.03 vs.113.27 +/- 89.03, p = 0.0025). LR patients experienced a greater degree of anaemia and a high prevalence of CVD at the time of dialysis initiation. Our data suggest that the anaemia, CV damage and progression of left ventricular hypertrophy (LVH) in the LR patients during haemodialysis treatment are associated with poor survival on haemodialysis.

Published
2008

25. Survival of patients on maintenance haemodialysis over a twenty-year period

Author

A, Sikole, V, Nikolov, P, Dzekova, N, Stojcev, V, Amitov, G, Selim, A, Asani, S, Gelev, R, Grozdanovski, G, Masin, H, Klinkmann, and M, Polenakovic

Subjects
Adult, Male, Survival Rate, Renal Dialysis, Humans, Kidney Failure, Chronic, Female, Middle Aged, Survival Analysis, Aged
Abstract

Patient survival is a key index of the overall adequacy of treatment in most chronic diseases. Analyses of survival of patients undergoing haemodialysis is very important, as it may offer clues and ideas for prolonging survival of patients with end-stage renal disease (ESRD). The aims of this study were to describe the characteristics of the patients on maintenance haemodialysis therapy over a period of 20 years, to determine the survival rate of these patients according to ages at the onset of haemodialysis, the primary renal diseases, and the cause of death, and to determine the survival rate at five, ten, fifteen and twenty years of haemodialysis treatment at our centre. The charts of 518 unselected patients, 282 male and 236 female, treated with maintenance haemodialysis therapy in a period of 20 years (1985-2005) were reviewed. At the time of evaluation, 164 patients were currently being treated, and 354 patients overall had been diseased. Statistical analysis was performed to evaluate the relationship between survival and patient characteristics such as age, gender, primary renal disease, and age at dialysis onset. Actual survival rates were determined by the Kaplan-Meier method. The survival rate of our patients treated with maintenance haemodialysis was 60% at 5 years, 37% at 10 years, 25% at 15 years and 9% at 20 years. Female patient survival was superior to male. Patients aged under 40 at the start of dialysis had a better survival probability compared to older patients. Patients with diabetes mellitus and nephroangiosclerosis, had a lower survival rate compared to patients with glomerulonephritis and with adult dominant polycystic kidney disease. Cardiac death was the most common cause of death in patients involved in the study. About 52% of the patients died from cardiovascular disease. Death is the most severe consequence of inadequate dialysis and can be used as an index of the adequacy of the dialysis therapy. Treatment factors that may improve outcomes include an early start of dialysis therapy, a high dose of dialysis (Kt/V over 1.2), correction of anemia, adequate protein and caloric intake, control of calcium and phosphate metabolism, and the use of biocompatible dialyzers.

Published
2008

26. Association between haemoglobin level and all-cause mortality in haemodialysis patients: the link with inflammation and malnutrition

Author

G, Selim, O, Stojceva-Taneva, A, Sikole, V, Amitov, L, Trajcevska, A, Asani, S, Trojacanec-Piponska, and M, Polenakovic

Subjects
Inflammation, Male, Hemoglobins, Renal Dialysis, Malnutrition, Humans, Kidney Failure, Chronic, Anemia, Female, Middle Aged, Serum Albumin
Abstract

Although anaemia management has improved in haemodialysis (HD) patients in recent years, many of them still have haemoglobin (Hb) levels below the current recommendations. The consequent anaemia could be one of the links between malnutrition and inflammation, and higher mortality in HD patients. The study objective was to determine the relationship between Hb levels and outcome in patients undergoing HD, accounting for inflammation and malnutrition. We retrospectively analysed a total of 236 patients on HD between January 2003 and December 2005, classified by absence or presence of inflammation and malnutrition (defined as serum albumin levels40 g/L and CRP8mg/l). Serum levels of Hb, ferritin, creatinine, cholesterol, triglycerides, HDL (high-density lipoprotein cholesterol), LDL (low-density lipoprotein cholesterol), albumin and CRP were measured monthly, fibrinogen was measured every third month. Over the period of three years, 73 out of 236 patients (30%) had died, most from cardiovascular diseases (62%). Presence of inflammation and malnutrition (in 44% of patients) was associated with older age (60.69 -/+ 12.46 vs. 54.52 -/+ 12.37, p = 0.0002), lower levels of Hb (99.53 -/+ 14.97 vs. 111.86 -/+ 10.38 g/l, p = 0.0000), creatinine (835.88 -/+ 179.84 vs. 1069.98 -/+ 821.23-/+mol/l, p = 0.0047), albumin (36.58 -/+ 3.41 vs.40.32 -/+ 2.82 g/l, p = 0.0000), cholesterol (4.32 -/+ 1.04 vs. 4.75 -/+ 1.09 mmol/l, p = 0.0025) and higher levels of fibrinogen (4.94 -/+ 1.18 vs. 4.29-/+0.91g/l, p=0.0000) and CRP (30.42-/+29.47 vs. 5.24-/+4.89 mg/l, p=0.0000). The Kaplan-Meier analysis showed that, irrespective of the absence or presence of inflammation and malnutrition, the all-cause mortality was higher in patients with Hb110g/l (Log-Rank, p=0.00147; p=0.00222). On the other hand, Kaplan-Meier showed that, irrespective of the absence or presence of anaemia (Hb110g/l and Hb110g/l), the all-cause mortality was higher in patients with the presence of inflammation and malnutrition (Log-Rank, p=0.00222; p=0.00263). The Cox proportional hazard analysis, adjusting for age, showed that only lower serum levels of Hb and higher CRP were associated with all-cause mortality (chi-square=110,306, p=0.0000). Our findings confirm the association of Hb levels110g/L with higher mortality among maintenance HD patients, especially in patients with the presence of inflammation and malnutrition. Further investigation of the relationships among anaemia, inflammation and malnutrition and survival is warranted.

Published
2007

27. Loss of heterozygosity and allelic imbalance in apocrine adenosis of the breast

Author

A G, Selim, A, Ryan, G A, El-Ayat, and C A, Wells

Subjects
Adult, Carcinoma, Loss of Heterozygosity, Breast Neoplasms, Allelic Imbalance, Middle Aged, Polymerase Chain Reaction, Apocrine Glands, Cell Transformation, Neoplastic, Humans, Female, Fibrocystic Breast Disease, Precancerous Conditions, Microsatellite Repeats
Abstract

Recently, there have been studies suggesting that apocrine adenosis of the breast is a putative precancerous lesion, despite the generally held view that apocrine adenosis is benign. Because apocrine adenosis is almost always present as a small area or areas, it cannot be easily studied by conventional methods. In this study, areas of apocrine adenosis were microdissected from archival paraffin-embedded tissue to examine loss of heterozygosity and allelic imbalance compared with normal breast tissue epithelium from the same patients. Seventeen cases of apocrine adenosis, four associated with carcinoma, were analyzed using polymorphic microsatellite markers and polymerase chain reaction for loss of heterozygosity/allelic imbalance at eight loci that were reported to show allele loss or imbalance in invasive and in situ breast cancer. Loss of heterozygosity/allelic imbalance was detected in six of 17 cases of apocrine adenosis; three of 12 (25%) informative cases at 1p (MYCL1), two of seven (28.6%) at 11q (INT2), one of three (33.3%) at 13q (D13S267), two of 12 (16.7%) at 16q (D16S539), and two of 10 (20%) at 17q (D17S250). Neither loss of heterozygosity nor allelic imbalance has been identified at 1p (D1S252), 17p (TP53), or 17p (D17S513). In two of the four cases associated with carcinoma, loss of heterozygosity/allelic imbalance was seen in the same allele as in the synchronous carcinoma. These results suggest that molecular alterations, such as loss of heterozygosity and allelic imbalance, identified in apocrine adenosis may constitute an early event in the pathogenesis of breast cancer; reinforcing the possibility of apocrine adenosis being a putative precancerous lesion.

Published
2001

28. c-erbB2 oncoprotein expression, gene amplification, and chromosome 17 aneusomy in apocrine adenosis of the breast

Author

A G, Selim, G, El-Ayat, and C A, Wells

Subjects
Adult, Cell Membrane, Centromere, Gene Amplification, Oncogene Proteins v-erbB, Middle Aged, Aneuploidy, Humans, Female, DNA Probes, Fibrocystic Breast Disease, Precancerous Conditions, In Situ Hybridization, Fluorescence, Chromosomes, Human, Pair 17
Abstract

Amplification of the c-erbB2 oncogene and numerical aberrations of chromosome 17 occur in human breast carcinomas. Apocrine adenosis (AA) of the breast has been shown occasionally to have c-erbB2 overexpression and a possible premalignant potential, but little is known about cellular level genetic alterations in AA of the breast. Fluorescence in situ hybridization (FISH) is a new approach to detect these. In this study, a series of AA was studied by immunohistochemistry for c-erbB2 protein expression and by FISH using dual colour DNA probes for the c-erbB2 gene and the centromeric region of chromosome 17. Cell membrane immunostaining was seen in 10/18 (55.6%) AA cases, but unequivocal c-erbB2 gene amplification or chromosome 17 aneusomy was not seen. The results of this study suggest that c-erbB2 overexpression without amplification may occur early in breast oncogenesis. Amplification and numerical chromosome aberrations may occur later in the pathogenesis of apocrine-derived breast carcinomas.

Published
2000

29. Motivational interviewing as educational program in improving cardiac risk factors control in patients post myocardial infarction

Author

S.M. Soliman and G. Selim

Subjects
medicine.medical_specialty, Rehabilitation, business.industry, medicine.medical_treatment, Saturated fat, Behavior change, Motivational interviewing, Infarction, Overweight, medicine.disease, medicine, Physical therapy, Smoking cessation, medicine.symptom, Cardiology and Cardiovascular Medicine, business, Educational program
Abstract

Introduction: Motivational interviewing (MI) is a counseling style that was developed as an alternative to more traditional counseling using direct persuasion. It uses the patient's responses to reinforce talk directed toward change. The study examines MI as a tool for promoting lifestyle change in patients post infarction particularly smoking cessation, decrease saturated fat intake and increase physical activity. Methods: 1850 post myocardial infarction patients were recruited over 2 years period and were randomly assigned to either usual follow up or MI educational program. Patients participated in a 30 min weekly education session for eight weeks. Follow up telephone calls after another 4 weeks. Results: After MI, 95% of patients reported self cessation of smoking versus 75% in usual care patients (p

Published
2013

30. P 53 suppressor gene and cathepsin D expression in correlation with cellular and humoral immunity in cutaneous leishmaniasis

Author

M A, Selim, S M, Nada, B E, Abaza, A G, Selim, A M, Mangoud, M E, Ramadan, and T A, Morsy

Subjects
Leishmania, Male, Immunity, Cellular, Animals, Antibodies, Protozoan, Humans, Leishmaniasis, Cutaneous, Female, Genes, p53, Cathepsin D, Gene Expression Regulation, Enzymologic
Abstract

A total of fifteen clinically and parasitologically proven adult cases of cutaneous leishmaniasis were studied for the demonstration of premalignant factor(s). The levels of antibodies against Leishmania parasite were measured with the indirect haemagglutination test (IHAT) and evaluated with the results of lymphoblast transformation test (LTT), a tumour suppressor gene (P53) and an asportic proteinase enzyme (Cathepsin D). Three patients (females) refused to be biopsied. The results showed a direct correlation between elevation of IHAT in 7/12 patients (Titers 1/128 to 1/512) and elevation of LTT in 7/12 patients (82 to 90%). On the other hand, two males with low (?) seropositive IHAT (1/64) and low LTT (2040%) gave positive P53 antibody and moderate (1) and marked (1) degrees Cathepsin D. So, it is concluded that cutaneous leishmaniasis infection particularly chronic one favours the premalignant changes in the granulomatous lesions.

Published
1996

31. Epidemiology & outcome in CKD 5D (1)

Author

W. Winkelmayer, J. Liu, A. Brookhart, H.-Y. Wang, W.-C. Kan, C.-C. Chien, T.-C. Fang, H.-F. Lin, Y.-H. Li, C.-H. Wang, C.-L. Chou, M. Yazawa, Y. Shibagaki, K. Kimura, S. Ohira, K. Ryo, T. Hasegawa, N. Hanafusa, Y. Tsubakihara, K. Iseki, H.-Y. Chen, I.-C. Cheng, Y.-J. Pan, Y.-L. Chiu, S.-P. Hsu, M.-F. Pai, J.-Y. Yang, Y.-S. Peng, T.-J. Tsai, K.-D. Wu, P. Dzekova-Vidimliski, G. Severova-Andreevska, S. Pavlevska, L. Trajceska, G. Selim, S. Gelev, A. Sikole, M. Hecking, A. Karaboyas, R. Saran, A. Sen, M. Inaba, W. H. Horl, R. Pisoni, B. Robinson, G. Sunder-Plassmann, F. K. Port, S. Chiroli, L. Perrault, D. Mitchell, C. Mattin, R. Krause, H. J. Roth, H.-J. Schober-Halstenberg, G. Edenharter, U. Frei, R. Wilson, M. Adena, P. Hodgkins, M. Keith, M. Smyth, C. Couchoud, R. Galland, N.-k. Man, J. Chanliau, V. Lemaitre, J. Traeger, G. von Gersdorff, O. Vega, M. Schaller, L. Usvyat, N. Levin, C. Barth, P. Kotanko, L. Rosales, S. Thijssen, H. Schmid, H. Schiffl, A. Romanos, S. Lederer, K. H. Chu, B. Lam, C. Tang, S. Wong, A. Cheuk, K. F. Yim, H. L. Tang, W. Lee, K. S. Fung, H. Chan, T. K. Ng, K. L. Tong, M. Doyle, A. Severn, J. Traynor, W. Metcalfe, J. Boyd, S. Cairns, J. Reilly, A. Henderson, K. Simpson, D. Tovbin, A. Douvdevani, V. Novack, A. Abd Elkadir, M. Zlotnik, Z. Djuric, N. Dimkovic, J. Popovic, Y. Furumatsu, S. Yamazaki, Y. Hayashino, M. Takegami, Y. Yamamoto, N. Kakudate, T. Wakita, T. Akizawa, T. Akiba, A. Saito, K. Kurokawa, S. Fukuhara, G. Voronovitsky, L. Pinelli, L. Paganti, J. Silva, R. Garofalo, E. Reiss, J. Gimenez Torrado, P. Lafroscia, M. Lugo, S. Laplante, P. Vanovertveld, M. Nordio, A. Limido, U. Maggiore, M. Nichelatti, M. Postorino, G. Quintaliani, L. Ebah, D. Kanigicherla, M. Nikam, G. Dutton, S. Mitra, L. Attipoe, J. Baharani, G. Magrini, A. Martorell, Y. Mashima, T. Konta, K. Kudo, K. Suzuki, A. Ikeda, S. Takasaki, I. Kubota, J. Chudek, K. Wieczorowska-Tobis, A. Wiecek, null Members of the \\'PolSenior\\' Study Group, J. M. des Grottes, F. Collart, H. Maheut, D. A. Goodkin, B. Bieber, B. M. Robinson, M. Jadoul, M. Djogan, I. Dudar, T. Sergeyeva, K. Yamagata, H. Nishi, S. Nishi, K. Hommel, M. Madsen, T. M. Blicher, A.-L. Kamper, I. Masakane, S. Ito, M. Seino, M. Ito, J. Nagasawa, H. C. Rayner, D. S. Fuller, B. W. Gillespie, H. Morgenstern, F. Tentori, R. L. Pisoni, J.-J. Wang, J.-C. Hwang, D. Mladenovska, G. Severova, V. Amitov, P. Yadav, J. J. Carrero, D. J. Jager, M. Verduijn, P. Ravani, J. De Meester, J. G. Heaf, P. Finne, A. J. Hoitsma, J. Pascual, F. Jarraya, A. V. Reisaeter, F. W. Dekker, K. J. Jager, H. Sammut, M. S. A. Ahmed, J. Sheppard, N. Attwood, G. Cserep, K. Sinnamon, I. Katsipi, A. Tatsiopoulos, C. Doulgerakis, P. Papanikolaou, E. Kardouli, G. Lamprinoudis, K. Kintzoglanakis, M. Gennadiou, J. Kyriazis, A. Granger Vallee, E. Covic, M. Morena, A. Fournier, B. Canaud, D. Bolignano, S. Rastelli, G. Curatola, G. Caridi, R. Tripepi, G. Tripepi, R. Politi, F. Catalano, D. Delfino, M. Ciccarelli, F. Mallamaci, and C. Zoccali

Subjects
Transplantation, medicine.medical_specialty, Nephrology, business.industry, Epidemiology, medicine, Intensive care medicine, business, Outcome (game theory)
Published
2011

32. Verrucae treated by levamisole

Author

Amira Sh. Soliman, A A al-Gendy, Ahmed M. Salem, Z. Tosson, Mohamed Amer, and A G Selim

Subjects
Adult, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Administration, Oral, Dermatology, Body weight, Placebo, Skin Diseases, Group B, Plantar warts, Double-Blind Method, medicine, Humans, Child, Common warts, Chemotherapy, business.industry, virus diseases, Levamisole, Middle Aged, medicine.disease, Surgery, In plane, Warts, business, medicine.drug
Abstract

To assess the role of levamisole in treatment of different types of warts, a double-blind study was conducted on 40 patients with different types of warts. Patients were divided into two equal groups, A and B. Group A received levamisole 5 mg/kg body weight on 3 consecutive days every 2 weeks for a period up to 5 months, while patients of group B received placebo for the same period. In group A, 12 patients showed complete cure (60%), two showed partial cure (10%), and the remaining six patients showed no response (30%). In group B, complete cure was achieved only in one case. The higher cure rate was observed in plane and common warts, while plantar warts showed no improvement with levamisole treatment.

Published
1991

33. Coulometric titration with higher oxidation states of manganese

Author

Robert G. Selim and James J. Lingane

Subjects
inorganic chemicals, Precipitation (chemistry), Inorganic chemistry, chemistry.chemical_element, Sulfuric acid, Disproportionation, Manganese, Biochemistry, Analytical Chemistry, Coulometry, chemistry.chemical_compound, chemistry, Environmental Chemistry, Qualitative inorganic analysis, Titration, Spectroscopy, Equilibrium constant
Abstract

The equilibrium constant for the disproportionation of +3 manganese into the +2 and +4 states in sulfuric acid media has been evaluated spectrophotometrically. The formal disproportionation constant varies from 10 -3 in 4 M sulfuric acid to 10 -4 in 7 M sulfuric acid at 25°. In 5 to 7 M sulfuric acid both +3 and +4 manganese are quite stable with respcct to both their reduction by water and to the precipitation of their oxides. The current efficiency for the generation of +3 manganese is nearly 100% in 2 to 7 M sulfuric acid solution, providing the concentration of +2 manganese is at least 0.2 M . A sulfuric acid concentration of about 6 M is most satisfactory when +3 manganese is generated for coulomctric titration because of the maximal stability of +3 manganese in this medium.

Published
1959

34. A Cytological Study of Oryza sativa L

Author

A. G. Selim

Subjects
Nucleolus, food and beverages, Cell Biology, Plant Science, Biology, Reticulate, Prophase, Meiosis, Evolutionary biology, Botany, Genetics, Animal Science and Zoology, Interkinesis, Ploidy, Telophase, Nucleolus organizer region
Abstract

1. Five races of rice plant have been cytologically examined, and the chromosome number is found to be the same in all of them, the haploid number being 12.2. The resting nucleus of the pellen mother-cells generally has a single nucleolus with one or more vacuoles and crystalline bodies.3. Two firmly and permanently attached nucleoli are seen during the early prophase stage in three of the races. The other two have a single large nucleolus each.4. The synizetic knot in most Gases is very compact and the threads are extremely delicate and not distinct.5. No continuous spireme is formed at the loosening of the synizetic knot, but the reticulate character of the threads is retained until later.6. The single or double nucleolus is attached to the thread at more than one point.7. Dark stained bodies are seen scattered all over the reticulate thread. Chromatin is aggregated around these bodies, the thread is constricted and the chromosomes are formed.8. The secondary nucleolus disappears during the development of the chromosomes, and the primary one remains spherical all through diakinesis.9. At late diakinesis the primary nucleolus fades away gradually until it disappears; at the same time fibrilla-like structures appear between the chromosomes.10. Comparison of the five varieties of rice studied, shows that although they all have the same size of nuclei and the same number of chromosomes, yet they differ characteristically in the nucleolar content of their pollen mother-cells. These differences are correlated with the absolute and relative size of the nucleoli, and also with the time when the secondary nucleolus is budded off from the primary (see Table 2).11. The above facts suggest that when the nucleolus divides it separates two different materials; and Supports the view that the secondary nucleolus contributes material to the chromosomes, while the primary may contribute to the spindle.12. No resting nuclei are formed during interkinesis; and at homotypic telophase twelve chromosomes could be distinguished.The writer wishes to express his sincerest gratitude to Professor R. RUGGLES GATES of King's College, University of London, under whose supervision this work was carried out, for his kindly advice and valuable criticism.

Published
1930

35. Effect of dieldrin and lindane on the growth and nodulation ofVicia faba

Author

K. G. Selim, S. A. Z. Mahmoud, and Mehreshan T. El-Mokadem

Subjects
High concentration, Soil Science, Plant physiology, Plant Science, Root system, Pesticide, Vicia faba, Horticulture, Dieldrin, chemistry.chemical_compound, Agronomy, chemistry, Shoot, Lindane
Abstract

The chlorinated hydrocarbon insecticides, dieldrin and lindane, were used at the normal and 20-fold rate. The plants were grown in pots containing clay soil. The results showed that whereas low and high concentrations of dieldrin as well as low concentration of lindane had no effect on the morphological characters of the shoot and root systems, high concentration of lindane had a harmful effect. Nodulation was slightly affected by low and high concentrations of dieldrin as well as low concentration of lindane. High concentration of lindane had a deleterious effect on nodulation.

Published
1970

36. Effect of dieldrin and lindane on soil microorganisms

Author

S A, Mahmoud, K G, Selim, and M T, el-Mokadem

Subjects
Clostridium, Bacteriological Techniques, Dieldrin, Soil, Bacteria, Nitrogen, Azotobacter, Actinomycetales, Hexachlorocyclohexane, Soil Microbiology
Published
1970

37. Rust-Resistant Wheats for Egypt

Author

James Philp and A. G. Selim

Subjects
Horticulture, Multidisciplinary, Biology, Rust
Abstract

OUR results resemble those obtained by Mehta and Pal1 in India so closely that we are prompted to report them here.

Published
1941

Catalog

Books, media, physical & digital resources
See catalog results